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Abbreviations 
DCIS  ductal carcinoma in situ 
LCIS  lobular carcinoma in situ 
IDC  infiltrating ductal carcinoma 
ILC  infiltrating lobular carcinoma 
ER  estrogen receptor 1 protein 
ESR1  estrogen receptor 1 gene 
PR  progesterone receptor 
HER-2  erythroblastic leukaemia viral oncogene homolog 2 (ERBB2) 
CGH  comparative genomic hybridization 
aCGH  array based comparative genomic hybridization 
FISH  fluorescence in-situ hybridization 
SNP  single nucleotide polymorphism 
NFIB  nuclear factor 1 B 
IHC  immunohistochemistry 
cdk  cyclin-dependent kinase 
CAM  cell-cell adhesion molecule 
MMP  matrix metalloproteinase 
DM  double minute 
HSR  homogeneously staining region 
H&E  haematoxylin and eosin 
BAC  bacterial artificial chromosome 
RNAi  RNA interference 
FCS  fetal calf serum 
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Summary 
Gene amplification is a major mechanism for overexpression of potential oncogenes in cancer. Several 
amplifications have already been described in breast cancer. In order to find new amplified regions, 
we screened 30 human breast tumors for gene amplifications using the Affymetrix SNP 10k 2.0 
microarrays. For this purpose, we developed a new analysis procedure leading to an increased signal-
to-noise ratio which allowed us the discovery of new small single gene amplicons (< 1 Mb). Two of 
them, the ESR1 gene on 6q25 and the NFIB gene on 9p24, were further investigated. Fluorescence in-
situ hybridization of these two genes was performed on a TMA comprising more than 2200 breast 
cancer samples.  
NFIB amplification was found in 5% of all breast cancers analyzed, but with an increased 
amplification rate in medullary carcinoma (19%). NFIB amplified breast cancers showed a higher 
Ki67 proliferation index. Functional analysis with RNA interference of the NFIB gene in three tumor 
cell lines suggested a proliferation supporting role of the NFIB protein in breast cancer. 
The ESR1 gene was amplified in 21% of the breast cancer samples analyzed. The ESR1 amplified 
patients defined a subgroup of ER positive breast cancer patients with prolonged survival, suggesting 
that patients with ESR1 gene amplification optimally benefit from hormonal therapy. Since this 
amplification was also found in histological benign and precancerous breast lesion, we suggest that 
ESR1 gene amplification is an early mechanism in breast cancer development. 
Furthermore, the use of potentially heterogeneous markers, like the Ki67 proliferation index on a 
breast cancer TMA was investigated. All expected associations between Ki67 and other previously 
analyzed molecular markers could be reproduced with high statistical significance using a breast 
cancer TMA containing only one tissue sample per tumor. This leads to the conclusion that 
associations with cell proliferation can be reliably analyzed in a TMA format. 
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1. Introduction 
1.1. Importance of this work 
In the last few years, the identification of gene amplifications has become of special interest since an 
association of a given amplification with pharmacological effects of drug treatments has been 
detected. New anti-cancer drugs do not act non-specifically to inhibit dividing cells, but are directed 
against particular molecular targets. Frequently, a genomic aberration underlies the pro-tumorigenic 
activity of these drug targets and members of this new class of anti-cancer agents act specifically 
against the proteins encoded by the affected genes. The first successful agent was Glivec/Gleevec 
(compound: Imatinib). It is a specific kinase inhibitor targeting the bcr-abl fusion protein, the product 
of a fusion gene created by a genomic translocation, also known as Philadelphia chromosome. 
Herceptin (compound: Trastuzumab) was the next agent of this new class of drugs. This medicament 
is based on a monoclonal antibody against the protein HER-2 and it is only effective if the patient's 
breast tumor carries a HER-2 gene amplification. Similarly, but still disputed, is the effectiveness of 
Tarceva (compound: Erlotinib) and Iressa (compound: Gefinitib). Both are suggested to act in non-
small cell lung cancer if an EGFR gene amplification is present. These findings, that a gene 
amplification is able to predict response to an anti-cancer agent and is therefore able to improve 
decision making on therapy and patient's outcome, encouraged us to focus our work on the discovery 
of new gene amplifications that in turn could lead to the identification of novel targets for highly 
specific drug therapies. 
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1.2. Breast Cancer 
1.2.1. Medical view 
Each year about 10 million new cases of invasive cancer arise world-wide. More than 10% of these 
cases arise in the breast. This makes female breast cancer the second most common site of malignant 
neoplasms after the lung (Parkin, 2001) (Figure 1).  
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Figure 1. Incidence of new cancer cases (in thousands). Adapted from (Parkin et al., 2005). 
 
 
Since most of the breast cancer cases affect only women (1% of the cases arise in men), breast cancer 
is the most common cancer in females. It accounts for about 22% of all new cancers in women (Figure 
2). In developed countries, this proportion rises to 27% (Vainio & Bianchini, 2002). The difference in 
the incidence between developing and developed countries is said to be due to the earlier detection in 
developed countries (higher screening possibilities) as well as the improvement in prognosis, since 
more and more therapies have become available. 
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Figure 2. Estimated numbers of new cancer cases (incidence) and prevalent cases in 2002. Adapted 
from (Parkin et al., 2005). 
 
Nevertheless, there are also environmental factors in the aetiology that contribute to a higher 
incidence: Low parity and late age at first pregnancy are consistently associated with an increased risk 
for breast cancer (Vainio & Bianchini, 2002). Increased life expectancy contributes also to a higher 
risk; as for most epithelial tumors, the risk increases steadily with the age. Although the incidence rate 
is rising, the mortality rate is decreasing in several western countries. This is due to improvements in 
diagnosis and therapy (Vainio & Bianchini, 2002), leading to a high prevalence of breast cancer 
patients in the population (Figure 2). In the United States, survivors of breast cancer constitute 1.5% of 
the female population (Hewitt et al., 1999). 
 
1.2.1.1. Classification of breast tumors 
Breast cancer is a heterogeneous disease in terms of clinical course and microscopic pathology. 
Although they can start in any tissue of the breast, most of them begin in the ducts (the milk-passages 
that connect the lobules to the nipple) or in the cells of the lobules (the milk-producing glands). The 
World Health Organization (WHO) classifies breast cancer due to its histological appearance, into 
noninvasive and invasive breast cancers (Coleman & Tsongalis, 2001; Fehr et al., 2006; Vainio & 
Bianchini, 2002): 
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Noninvasive breast cancers:  
There are two main types of noninvasive breast cancers: the ductal carcinoma in situ (DCIS) and the 
lobular neoplasia (also called lobular carcinoma in situ, LCIS). The cancer cells of these forms are 
either located inside the ducts (DCIS) or inside the lobules (LCIS). Both types are so-called "in-situ" 
because they do not invade the surrounding fat tissue, nor spread through other organs in the body. 
DCIS is classified as precancerous disease, since 30-40% of the DCIS cases would pass into an 
invasive breast cancer, if they would not be treated. In contrast to DCIS, LCIS is not classified 
precancerous, since it will only rarely advance to an invasive cancer. But patients with this condition 
will still have a higher risk of developing an invasive breast cancer, either in the same breast or in the 
opposite one. 
Invasive breast cancers: 
Most of the invasive breast cancers (about 80%) are infiltrating (or invasive) ductal carcinomas 
(IDCs). These tumors start in the duct of the breast, brake through the wall of the duct and invade the 
surrounding fat tissue, from where they can spread through the lymphatic system or bloodstream. The 
other main type of invasive breast cancers (about 10-15%) is the infiltrating (or invasive) lobular 
carcinoma (ILC). These cancers begin in the lobules of the breast and act then similarly to the IDCs. 
Less frequent than the ILCs are the medullary carcinomas. The proportion described in the literature 
ranges between 5% and 10%. This special type of invasive breast cancer was named in this way for its 
similarity in color to brain tissue (medulla). Nevertheless, they are difficult to distinguish from IDC 
and are therefore often treated the same way, although the prognosis for medullary breast carcinomas 
is better than for other types of invasive breast cancer (Rubens et al., 1990). Other rare types of 
invasive breast cancer are inflammatory breast cancer and tubular carcinoma (each about 2%), and 
even rarer (less than 1%) are mucinous carcinomas, paget disease of the nipple and phyllodes tumor.  
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1.2.2. Molecular biological view 
The human body can be seen as a micro-ecosystem consisting of billions of cells, each with a defined 
role behaving in a socially responsible manner. In such a system it is not surprising that cell growth is 
tightly controlled (Alberts et al., 2000). A molecular disturbance, i.e. a heritable change like a 
mutation, can give to the single cell carrying this mutation the ability to circumvent the strict cell 
growth control mechanisms. This can allow the cell to divide more quickly than its adjacent cells and 
become the founder of a new cell mass, called a tumor. As long as these tumor cells do not have the 
ability to invade the surrounding tissue, they are called benign. The conversion of such a cell into a 
neoplastic (also invasive) state is a multi-step process and requires the accumulation of several 
mutations (Coleman & Tsongalis, 2001). Indeed, up to 10 mutations are needed to become malignant 
and to have the ability to invade the surrounding tissue or to metastasize using the bloodstream or the 
lymphatic system as a carrier and to colonize other organs of the human body (Alberts et al., 2000; 
Coleman & Tsongalis, 2001). These tumor-promoting mutations typically affect three major classes of 
genes: proto-oncogenes, tumor suppressor genes and stability genes (caretakers) (Vogelstein & 
Kinzler, 2004). The latter act in a different way than oncogenes or tumor suppressor genes, because 
they do not influence cell growth or cell proliferation directly. The normal function of stability genes 
is to keep genetic alterations to a minimum (Vogelstein & Kinzler, 2004). They are either involved in 
DNA repair mechanisms (mismatch repair, nucleotide-excision repair, base-excision repair) or in the 
control of processes, which involve larger portions of chromosomes, like mitotic recombination and 
chromosomal segregation. When these genes cannot function in a proper way (because of a mutation 
or of a loss), the cells become genetically instable and genetic alterations in other genes can occur at a 
higher rate (Cahill et al., 1999; Vogelstein & Kinzler, 2004). Genome instability is a process which 
may develop after tumor initiation, i.e. during tumor progression, for example by a malfunction of 
p53, the so-called "guardian of the genome" (Alberts et al., 2000). Nevertheless, the progressive 
destabilization of the genome of a cancer cell is a common event in all cancers and is a prerequisite for 
the tumor cells to gain the abilities that are necessary for malignant growth. These so-called six 
hallmarks of cancer (Hanahan & Weinberg, 2000) are said to be the critical features that are 
INTRODUCTION 
 
 13
responsible for the phenotype that we recognize as cancer: self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis. These properties may also apply to breast cancer: 
Self-sufficiency in growth signals: 
As mentioned before, cell proliferation is a process that is rigidly controlled. Growth signals are 
required to switch the cells from a quiescent state into a proliferative state (Hanahan & Weinberg, 
2000). These growth signals are ligands of receptors that will induce the activation of specific 
signaling pathways, thus leading to activation of gene transcription. Growth factors, like the 
transforming growth factor alpha (TGF-α) and insulin-like growth factor-1 (IGF-1) stimulate benign 
breast growth. Uncontrolled expression of these signals can become important drivers of self-
sufficient growth in breast cancer (Humphreys & Hennighausen, 2000; Schroeder & Lee, 1997; 
Sledge & Miller, 2003). Overexpression of receptors can lead the tumor cell to become 
hyperresponsive to ambient levels of growth factors that normally would not trigger cell proliferation 
(Hanahan & Weinberg, 2000). The estrogen receptor (ER), a steroid hormone receptor in the nucleus 
and the HER-2 receptor, a transmembrane receptor tyrosine kinase, are both prominent examples of 
overexpressed receptors in breast cancer. Both of them have become important therapy targets. 
Insensitivity to antigrowth signals: 
To maintain the cells in a quiescent state, several anti-proliferative signals are necessary. These so-
called negative controls fail to function properly in cancer. Many of these negative feedback loops 
involve proteins, which are key players of the cell-cycle protein machinery. This machinery consists of 
cyclins, which form complexes with their specific cyclin-dependent kinases (cdks) leading to the 
activation of their kinase function. In breast cancer, the importance of the insensitivity to antigrowth 
signals, either by overexpression of cyclins and/or by downregulation of the cdk-inhibitors, have been 
shown in several studies: Overexpression of Cyclin D1 occurs at a relatively early stage (Heffelfinger 
et al., 2000) and increased levels of Cyclin E and its related cdk (Keyomarsi et al., 2002) or 
downregulation of the cdk-inhibitor p27 are associated with worse outcome  (Tan et al., 1997; Thor et 
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al., 2000; Tsihlias et al., 1999). The loss of cdk inhibitors may also be caused by loss of TGF-β 
signaling, which can be an early event in breast cancer (Donovan & Slingerland, 2000), either by loss 
of TGF-β production or through mutational inactivation of the TGF-β receptors (Baxter et al., 2002; 
Chen et al., 2006; Fynan & Reiss, 1993). 
Evasion of apoptosis: 
The ability of tumor cells to expand in number is not only limited by the rate of proliferation, but also 
by the rate of programmed cell death (apoptosis), which antagonizes the proliferative effect (Hanahan 
& Weinberg, 2000). Therefore, in order to increase its cell number, the tumor has to acquire resistance 
towards apoptosis. This can be achieved in different ways, for example by downregulation of bcl2, an 
anti-apoptotic gene with lower expression in the majority of the breast cancers or by mutation of p53, 
which in its normal state is able to induce apoptosis. Mutation of p53 occurs in 25-45% of primary 
breast cancers (Osborne et al., 1991). 
Limitless replicative potential: 
Mammalian cells carry an intrinsic program that limits the number of multiplications a cell is able to 
perform. This program is effectuated by the progressive loss of the telomeres, each time a cell divides. 
With each cell cycle, the telomeres become progressively shorter, resulting in senescence and cell 
death (Alberts et al., 2000; Coleman & Tsongalis, 2001; Hanahan & Weinberg, 2000). For a tumor 
cell to become immortal, it is necessary to disrupt this program. This can be achieved by telomere 
maintenance due to increased levels of telomerase, an enzyme that adds specific DNA sequence 
repeats to the 3' ends of the telomeres of the DNA strands. The human telomerase catalytic subunit 
gene (hTERT) has been found to be activated in over 90% of the breast tumors (Herbert et al., 2001), 
including pre-invasive tumors (Mueller et al., 2002; Shpitz et al., 1999). But no expression was 
observed in the adjacent normal tissue (Herbert et al., 2001). 
Sustained angiogenesis: 
The formation of new blood vessels is crucial for nourishing the tumor, especially if invasion and 
metastasis will occur (Folkman, 1971). In healthy adults, the normal vasculature is quiescent, with 
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each endothelial cell dividing once every 10 years (exceptions: wound healing, endometrial 
proliferation, postlactational mammary gland involution and pregnancy) (Sledge & Miller, 2003). In 
order to stimulate the vascular endothelial cells, i.e. to induce angiogenesis, the tumor cells have to 
activate the switch by changing the balance of angiogenic inducers and countervailing inhibitors 
(Hanahan & Weinberg, 2000). The most prominent angiogenic inducer is VEGF (vascular endothelial 
growth factor). In breast cancer, VEGF has been to be markedly upregulated in comparison to the 
surrounding normal tissue (Kawai et al., 2002). 
Tissue invasion and metastasis: 
A hallmark of the malignant phenotype of a cancer is the ability to invade through the basement 
membrane, i.e. the transition from a non-invasive to an invasive phenotype. Metastases, which are the 
cause of about 90% of human cancer deaths, can be seen as an extension of local invasion. To gain 
this capability, tumor cells have to alter several classes of proteins, which are responsible either to 
couple the cells to their environment (cell-cell adhesion molecules CAMs, integrins), or to degrade the 
basement membrane and the surrounding stroma, like matrix metalloproteinases (MMPs). MMP-2 and 
MMP-9 are two prominent examples, whose expression in breast cancer was found to be associated 
with stage and grade (Kossakowska et al., 1996; Zucker et al., 1993). 
 
Finally, it has to be considered that the sequence how these hallmarks are acquired, i.e. how a tumor 
becomes physiologically a "successful" cancer, varies from patient to patient (Sledge & Miller, 2003): 
a mutation in a certain oncogene or in a tumor suppressor gene can occur early in some tumors, and 
late in others. 
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1.2.2.1. Biomarkers in breast cancer 
Several of the above mentioned oncogenes and tumor suppressor genes are used as molecular markers, 
also called biomarkers. By analyzing biological tumor features in breast cancer, discrimination 
between diagnostic, prognostic and predictive markers is not always unproblematic. Diagnostic 
markers are routinely used by pathologists to facilitate the diagnosis. The most prominent ones are the 
cytokeratins and E-cadherin. Cytokeratins are also used as support for differentiation between benign 
and malignant breast lesions (Moriya et al., 2006). E-cadherin is a calcium regulated adhesion 
molecule, which is a central component of cell-cell adhesion junctions. Under normal circumstances, it 
is expressed in most epithelial tissues (Takeichi, 1990). E-cadherin is suggested to act as a tumor 
suppressor protein, since its loss can cause dedifferentiation and invasiveness in human carcinomas 
(Frixen et al., 1991; Larue et al., 1994). In the last few years, loss of E-cadherin has been consistently 
observed at sites of epithelial-mesenchymal transitions (EMT) during development and cancer 
(reviewed in (Kang & Massague, 2004)). In breast cancer diagnostics, E-cadherin is used as a marker 
to distinguish lobular from ductal carcinomas since its expression is almost undetectable in lobular 
tumors by immunohistochemistry (Moriya et al., 2006).  
Many genes have been classified as prognostic factors in breast cancer. These factors provide 
information on outcome, independent of the chosen adjuvant therapy. The most prominent ones are 
summarized in Table 1. Most of them have already been mentioned when introducing the hallmarks of 
cancer: HER-2, ER, PR and EGFR are all receptors and can be categorized in to the "self-sufficiency 
in growth signals"; Cyclin A, B, D, E and p27 are cell-cycle components belonging to "insensitivity to 
anti-growth signals"; bcl-2 and survivin are involved in "evasion of apoptosis", and the telomerase 
hTERT has been introduced as an enzyme necessary for a tumor cell to get "limitless replicative 
potential". 
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Marker Positive breast tumors (%) Association with: Reference
HER2 15-30 worse prognosis Tsutsui et al.; Surgery, 2003
ER 70 good prognosis Torhorst et al.; Am J Pathol., 2001
PR 60 good prognosis Torhorst et al.; Am J Pathol., 2001
EGFR 36 worse post-relapse survival Tsutsui et al.; Clin Cancer Res, 2002
Cyclin A 8 (0-51) worse prognosis in node-negative patients Kuhling et al.; 2003, J Pathol.
Cyclin B 5 (0-75) worse prognosis in node-negative patients Kuhling et al.; 2003, J Pathol.
Cyclin D 42 no real association, controversial results Gradishar; Breast Cancer Res Treat., 2005
Cyclin E 10 (0-90) worse prognosis Keyomarsi et al.; NEJM, 2002
p27 80 good prognosis Lloyd et al.; J. Pathol, 1999
p53 20-40 worse prognosis Borresen-Dale et al.; Human Mutat, 2003
bcl-2 30-40 good prognosis Chang J et al; Cancer, 2003
Survivin 80 cytoplasmic: worse prognosis Sohn et al; Biomed Pharmacother, 2006
hTERT 59 short survival Poremba et al; J Pathol, 2002  
Table 1: Prognostic biomarkers in breast cancer. Numbers in parenthesis represent the range. All these 
markers have been analyzed by immunohistochemistry. Modified from (Coradini & Daidone, 2004). 
 
The most informative markers for the patients are the predictive ones. Unfortunately, these markers 
are often confused with the above described prognostic markers. In contrast to prognostic markers, 
predictive markers are used to select responsiveness or resistance to a specific treatment (Duffy, 
2005). Usually, predictive markers are prognostic too, but not vice versa. Currently, the American 
Society of Clinical Oncology recommends routine testing of three predictive markers for decision 
making on therapy in breast cancer: the estrogen receptor ER, the progesterone receptor PR and the 
human epidermal growth factor receptor-2 (HER-2) (Bast et al., 2001). Testing of ER and PR 
positivity in breast cancer is used for predicting response to hormone therapy. Initially, this therapy 
included oophorectomy (ovarian ablation). Current hormonal therapy is called "anti-estrogen therapy" 
and is more focused on the estrogen receptor, since only 5% of breast cancers are ER negative and PR 
positive, and only 10% of that subgroup will respond to hormonal therapy. Anti-ER treatment 
strategies include blocking by selective modulators (e.g., Tamoxifen), destabilization and degradation 
by selective downregulators (e.g., Fulvestrant) and disruption of estrogen synthesis (e.g., Anastozole). 
At the moment, it is unknown why only 70% of the ER+/PR+ and only 33% of the ER+/PR- do 
respond to these therapies. 
The third predictive marker routinely used in breast cancer involves the HER-2 gene. It belongs to the 
EGF receptor family of receptor tyrosine kinases. Other members of this family are the HER-1 
(EGFR), HER-3 and HER-4 receptors (Duffy, 2005). Ligand binding of these transmembrane 
receptors promotes dimerization leading to an activation and thus to an increased tyrosine kinase 
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activity (Burgess et al., 2003). In contrast to these members, no directly binding ligand has been 
identified for the HER-2 protein. It is suggested that the HER-2 receptor has a high level of 
constitutive activity and thus it is willing to form heterodimers with ligand activated forms of other 
HER receptors (Burgess et al., 2003). In human breast cancers, amplification and overexpression of 
the HER-2 gene are found in 15-30% of primary invasive tumors (Duffy, 2005), causing a very 
aggressive form of breast cancer. Several monoclonal antibodies against the HER-2 ectodomain were 
developed; one of these, also known as 4D5, was later modified for administration to patients and 
termed trastuzumab, the active component of the medicament Herceptin (Carter et al., 1992). The food 
and drug administration FDA has approved Herceptin for treating metastatic HER-2 positive breast 
cancers. Administration of Herceptin together with chemotherapy led to the shrinking of tumors of 
nearly half the women (45%) treated (Slamon et al., 2001). Currently, clinical trials with women 
carrying non-metastatic HER-2 positive breast cancer are in progress. 
 
1.2.2.2. Molecular expression patterns in breast cancer 
It was obvious that the two most prominent markers, the ER and the HER-2, would influence the gene 
expression patterns of breast cancer cells. Therefore, genetic classification of breast cancers based on 
RNA expression arrays has been performed several times. However, only the study of Perou and 
Sorlie (Perou et al., 2000; Sorlie et al., 2001) was reproduced on different data sets resulting in the 
same classification pattern (reviewed in (Sorlie, 2004)). Their genetic subtyping was based on the 
variation in expression patterns observed in 115 breast cancer samples. They selected an intrinsic set 
of 415 genes, followed by hierarchical clustering of all the samples based on this gene set. They 
distinguished two main classes of tumors, one with the characteristics of basal cells, the other of 
luminal cells. The so-called basal tumors expressed CK5 and CK17, but were ER negative, whereas 
the luminal phenotype was based on the expression of CK8/18, CK19 and a cluster of transcription 
factors including the estrogen receptor. This two-class model was further refined and several 
subclasses were created. One of these subclasses, which branched close to the basal-like cases, was 
characterized by the overexpression of the HER-2 gene, suggesting these samples to be the ones with 
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17q21 amplification. Survival analyses of these groups revealed worst survival for the HER-2 and 
basal-like group and best survival for the luminal group. This was not surprising, since ER positive 
patients of this study had been treated with Tamoxifen. Later, the luminal group was further 
subdivided into two subgroups, the luminal A group with high ER expression and the luminal B group 
with low to moderate ER expression. Results from different DNA microarray platforms obtained on 
different breast cancer sets (e.g. Van't Veer set, West set) with variations in technology and statistical 
analysis, provided highly consistent classification results. Recently, Calza et al (Calza et al., 2006) 
applied a similar analysis procedure to a public available Swedish breast cancer set (Pawitan et al., 
2005), leading to the same discrimination of these subgroups. The existence of these subclasses has 
been reinforced at the protein level; using immunohistochemistry on tissue microarrays, the same or 
similar subclasses of tumors have been observed (Callagy et al., 2003; Korsching et al., 2002; van de 
Rijn et al., 2002). 
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1.3. Gene amplification in cancer 
There are three types of genetic alterations that can transform a cancer-critical gene into an oncogene: 
a deletion or a mutation in the coding sequence (e.g. EGFR), a chromosome rearrangement, like the 
creation of a fusion protein (e.g. Bcr-Abl fusion gene) and the amplification of a specific DNA 
sequence.  
Amplifications are mutations that result in multiple copies of genes in amplified chromosomal regions 
(so-called amplicons). In contrast to other organisms (e.g. oogenesis fruitfly) (Spradling & Mahowald, 
1980), amplification in mammals is an unscheduled process. It can be seen as a common genetic 
mechanism for upregulating gene expression in cancer (Schwab, 1999). But the number of 
overexpressed genes in the amplified chromosomal regions varies depending on the cancer tissue and 
also on the study (Myllykangas et al., 2006; Myllykangas & Knuutila, 2006): In prostate cancer cell 
lines, 19.3% of the amplified genes were found to be overexpressed (Wolf et al., 2004). In breast 
tumors the fraction ranges between 44% (Hyman et al., 2002) and 62% (Pollack et al., 2002). 
Especially, advanced cancers, which have lost p53-mediated maintenance of genomic integrity or 
other genes involved in the apoptotic disruption of damaged cells, are affected by these chromosomal 
rearrangements (Livingstone et al., 1992; Yin et al., 1992). Due to variable sizes of the different 
amplicons, it remains a challenge to identify the driving genes, which are amplified and 
overexpressed, and give growth advantage to the tumor cell. Mostly, the driving genes of the 
amplicons are well-known oncogenes: for example the protein kinase AKT2 (14q32) in ovarian 
cancer; the v-myc viral oncogene homolog 1 (MYCL1; 1p34) in small cell lung cancer and glioma; 
MYCN (2p24) in about 20% of neuroblastoma; HER-1 (EGFR, 7p12) in glioma and non-small cell 
lung cancer or HER-2 (17q21) in 15-30% of breast tumors (Futreal et al., 2004; Myllykangas & 
Knuutila, 2006; Schwab, 1999).  
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1.3.1. Mechanism of gene amplification 
Although the role of gene amplification in cellular transformation of human cancers is indisputable, 
the precise mechanisms how amplifications develop have not been entirely determined. 
There are two types of cytogenetic manifestation of gene amplification: extrachromosomal double 
minutes (DMs) and intrachromosomal homogenously staining regions (HSRs). Double minutes are 
small circular DNA fragments, lacking a centromere and a telomere (Barker, 1982). It has been 
suggested, that they replicate autonomously, since they also contain replication origins (Carroll et al., 
1993; Carroll et al., 1987). But the most popular model for the development of gene amplification is 
the breakage-fusion-bridge (BFB) model. Initially, this model leads to an intrachromosomal amplicon, 
which can excise itself and become an extrachromosomal double minute (Coleman & Tsongalis, 
2001). The BFB-model was first described in 1942 (McClintock, 1942) and has been remodeled by 
several investigators leading to the actual model presented in figure 3 (Bailey & Murnane, 2006). It is 
suggested that an intrachromosomal gene amplification is the product of several rounds of BFB cycles. 
 
 
Figure 3. The bridge-fusion-model as actual model for the development of intrachromosomal gene 
amplification. Squares: telomeres, circles: centromeres, horizontal arrows: orientation of sequences. 
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The first step of the BFB model is the generation of a double-strand break (DSB). Next, the broken 
molecule is replicated and the sister chromatids fuse and form a bridge during anaphase. 
Asymmetrical breakage due to mechanical tension will lead to one daughter cell with a copy of the 
chromosome with an inverted repeat at the broken end, and one daughter cell owing a chromosome 
with a terminal deletion. Several rounds of BFB cycles would lead to the above mentioned HSR, 
which would be in line with the observation that HSRs are often organized as an inverted ladder and 
are often associated with a deletion from the amplicon towards a telomere (Bailey & Murnane, 2006; 
Haber & Debatisse, 2006; Narayanan et al., 2006). Nevertheless, it has to be considered that although 
mammalian cells have a robust non-homologous end joining machinery, the fusion of broken 
chromatids has never been directly demonstrated (Narayanan et al., 2006). 
 
1.3.2. Detection of gene amplifications 
The first method used for the detection of amplifications or other chromosomal changes was the use of 
conventional cytogenetics, in which chromosomal abnormalities are detected microscopically in cells 
arrested at methaphase. This procedure results in the typical black and white alternating banding 
pattern produced by the different staining methods (e.g. Q-banding, R-banding, G-banding). The use 
of this so-called chromosome banding for the detection of new amplifications in cancer is restricted by 
the limited cytogenetic information that is available from solid tumors, since it is difficult to culture 
neoplastic epithelial cells to bring them into metaphase, and by the low chromosome band-specific 
resolution of approximately 20 Mb. In 1992, the analysis of chromosomal changes in human 
malignancies was boosted by the development of the comparative genomic hybridization (CGH) 
(Kallioniemi et al., 1992). This molecular-cytogenetic method is based on the competitive 
hybridization of fluorescently labeled tumor DNA (e.g. Fluorescein, FITC) and normal DNA (e.g. 
Rhodamin-labeled) to normal human metaphase chromosome preparations. The fluorescence color 
ratio along the chromosome is used to evaluate regions of DNA loss or gains (Figure 4). However, the 
use of metaphase chromosomes limits detection of events involving small regions (less than 10 or 20 
Mb) of the genome. 
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Figure 4. CGH: Comparative genomic hybridization. A) shows an overview of the steps involved in 
CGH (from Michael Baudis, www.progenetix.net). B) shows the result of a successful CGH (6p22 
amplification). 
 
Once an amplified region is identified, the suspected amplified genes need to be verified by Southern 
Blot or FISH (Fluorescence in Situ Hybridization). In both methods, the location of the gene or region 
of interest has to be known exactly since a specific probe has to be created. In 1997, Pinkel et al 
suggested that the hybridization of the fluorescently labeled probes to an array of mapped sequences 
instead of metaphase chromosomes could overcome the limitations of conventional CGH (Pinkel et 
al., 1998). This new technique was called array- or matrix CGH. The current sensitivity of this method 
is limited by the spacing of genomic clones used to construct the arrays (Mosse et al., 2005). 
Microarray platforms manufactured using BAC clones (Cai et al., 2002), cDNA clones (Pollack et al., 
1999) and oligonucleotides (Carvalho et al., 2004) have been developed for aCGH. The theoretical 
resolution can be increased up to 200-300 kb, by choosing targets, which are positioned in the genome 
near to each other. Indeed, the minimal size of the amplicons detected has never been smaller than 1 or 
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2 Mb, due to the noise generated in the data when analyzing up to 40'000 probes at the same time 
(Myllykangas & Knuutila, 2006). Affymetrix, as leading manufacturer of commercial microarrays, 
designed a microarrays series for the analysis of single nucleotide polymorphisms (SNPs). Due to the 
distribution of the SNPs across the whole genome, their signals on these so-called SNP arrays can be 
used for the calculation of whole genome DNA copy numbers. As usual for Affymetrix, they do not 
apply competitive hybridization, since they use their single channel technology. Comparison of the 
acquired signals to a reference array or set of arrays must be done after the acquirement of the signals. 
As for aCGH technology, the resolution of this method depends on the number of probes available on 
the array. Affymetrix started with the 10K chip containing 11'555 SNPs, corresponding to an average 
distance between two SNPs of 210 kb, and promotes now its newest 500K chip with more than 
500'000 SNPs and an average distance of 5.8 kb (Affymetrix, Product Sheet). Again, these numbers 
represent theoretical values, and the practical resolution that can be used for the final analysis, is lower 
and is dependent on the signal-to-noise ratio. This signal-to-noise ratio depends on several factors, 
such as heterogeneity of the starting material, noise generated in the different protocol steps and 
during the acquirement of the signals, and finally, the algorithm used for the analysis of the raw data. 
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1.4. Validation of candidate genes 
The completion of the sequencing of the human genome has provided the research community with 
comprehensive information about the existence and location of nearly all human genes (Lander et al., 
2001; Venter et al., 2001). Based on these data, several high-throughput analysis methods have 
become possible, such as cDNA microarrays for expression analysis or aCGH/SNP chips for detection 
of DNA copy number. Thus, analysis of tens of thousands of data points (i.e. genes) in one experiment 
has become possible, leading to the generation of several hundreds of candidate genes requiring only 
few experiments. For the validation of candidate genes, the reverse approach becomes appealing: the 
analysis of a candidate gene in hundreds or maybe thousands of tissues. This is particularly important 
in cancer classification, since there are several aberrant pathways that can lead to morphologically 
identical tumors. Thus, analysis of large numbers of tumors is necessary to obtain a full representation 
of the spectrum of relevance concerning the candidate gene. The validation of candidate genes with 
immunohistochemistry (IHC) for expression analysis or FISH for DNA copy number analysis can 
theoretically be performed on large tissue sections as usually used in pathology. However, the analysis 
of thousands of such slides for one candidate gene would lead to tremendous costs and exhaustion of 
valuable tissue archives. To overcome these shortcomings, the tissue microarray (TMA) technique was 
developed (Kononen et al., 1998). 
 
1.4.1. Tissue microarrays 
The tissue microarray technology allows the simultaneous analysis of up to 1'000 different tissue 
samples from routinely formalin-fixed paraffin blocks on a single microscope glass slide. The 
manufacture of these TMAs is done by taking minute tissue cylinders (typically 0.6mm in diameter) 
from different primary tumor blocks (the so-called donor blocks) and subsequently assembling them in 
an array-like format into an empty recipient block (Figure 5A). Regular microtomes can be used to cut 
sections from these TMA blocks to further perform in-situ analysis, like IHC and FISH (Figure 5B-E). 
Usually, only one spot with a diameter of 0.6mm of each tumor is sufficient for these kinds of 
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analyses. Several studies have shown that highly representative data about biomarkers in cancer can be 
obtained on the TMAs (Hoos et al., 2002; Nocito et al., 2001; Torhorst et al., 2001). However, it has 
been doubted if markers with heterogeneous expression patterns between different tumor areas, can 
reliably be determined using a single tissue core per tumor (Hoos et al., 2001). This may be a problem 
for the determination of the Ki67 labeling index (Ki67 LI), which shows considerable heterogeneity in 
breast tumors. The determination of the number of Ki67 expressing cells has become a standard 
procedure to assess the proliferative activity of tumor cells on tissue sections. The Ki67 LI marker has 
never been applied on a breast cancer TMA so far. But its successful application would not only help 
to determine the association of novel biomarkers with proliferation, but also prove the applicability of 
potential heterogeneous biomarkers on breast cancer TMAs. 
Figure 5. TMA manufacturing and applications. A) Cylindric tissue cores are removed from a donor 
block (a) and transferred to a recipient block (b). 4-8um sections are cut with a regular microtome 
using an adhesive tape (c) and placed on a microscopic slide (d).  B) Overview of a haematoxylin-
eosin (H&E) stained TMA section. C-E) Magnifications of spots from breast cancer TMA. C) H&E 
staining. D) IHC of Her-2. E) FISH of HER-2, showing red signals for HER-2 gene copies and green 
signals for the centromere 17. Adapted from (Sauter et al., 2003). 
 
Nevertheless, the IHC analysis on TMAs is clearly limited by the availability of antibodies that are 
suited for formalin-fixed tissues and by the non-automated manual scoring of the intensity signal. The 
first limitation can be circumvented by the use of TMAs with frozen tissues (so-called frozen TMAs) 
(Schoenberg Fejzo & Slamon, 2001). However, the creation of frozen TMAs is limited by the 
availability of frozen tissues and by the fact that the blocks have to be kept frozen through and after 
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the arraying process. The second drawback is the limitation of the manual (and subjective) scoring of 
the intensity, i.e. the quantification of the signal. To overcome these limitations, the use of protein 
lysate arrays seemed to be a promising methodology worth developing. 
 
1.4.2. Protein lysate microarrays 
There are two major classes of protein lysate arrays currently under development: forward-phase 
protein arrays (FPAs) and reverse-phase protein arrays (RPAs). In FPAs, the analytes of interest are 
captured from the solution phase (lysate) by the spotted capture molecule, which is usually an 
antibody (Liotta et al., 2003; Pavlickova et al., 2004). One spot contains one type of immobilized 
antibody, thus an array can contain up to several hundreds of different antibodies. Since each array is 
incubated with one test sample, this approach is reminiscent of cDNA arrays, where one sample is 
analyzed for several "targets". More similar to the TMA approach, is the second major class of protein 
lysate arrays, the reverse-phase protein arrays. In this format, the test samples (lysates) are 
immobilized as spots to yield an array that consists of hundreds of different lysates. Each array is 
analyzed by one detection protein (i.e. antibody), leading to the measurement of one analyte end point 
across all samples. Due to the small volume necessary for a lysate spot (approximately 0.1-0.3 nl), it is 
possible to spot each sample in several replicates and in serial dilutions. The possibility of using a dual 
channel detection system (for example a Cy3-labeled antibody for the visualization of the protein of 
interest and Cy5 for a housekeeping protein) in combination with the availability of serial dilutions of 
the samples, allows the determination of the dynamic range for the detection of the specific antibody, 
and thus the quantification of the signal. The successful application of such a system would overcome 
the above mentioned limitations of traditional TMAs. It would allow the use of a large number of 
different antibodies. In combination with an automated analysis of the generated fluorescent signal, 
this would ideally not only give rise to a quantification of a specific protein amount, but also to a 
major increase in the sensitivity of detection. 
INTRODUCTION 
 
 28
Thus, it would become feasible to analyze the activation status of signal transduction pathways in 
cancer, by quantifying and comparing the phosphorylation status (using phosphorylation specific 
antibodies) of signal transduction molecules in hundreds or even thousands of tumors. 
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1.5. Aims of the thesis 
This work has been divided into two major parts. This subdivision is also reflected in the structure of 
the results.  
The aim of the first part (Part A) was to elucidate the influence of breast tumor tissue heterogeneity on 
marker evaluation using breast cancer TMAs. For this purpose, we decided to analyze the Ki67 LI 
marker as one of the most heterogeneous marker on the breast cancer prognosis TMA. The obtained 
data will be compared to ten different biomarkers (HER2, MDM2, Egfr, MYC, CCND1, ER, PR, p53, 
p16, bcl2), many of which have been previously related to proliferative activity in breast cancer. Its 
successful correlation would allow us to trust the impact of new biomarkers on proliferative activity 
using breast cancer TMAs. 
 
The second part (Part B) comprised a screening of 30 breast cancer samples with the objective of 
finding new amplifications. For this screening, we decided to use the relatively new technology of the 
Affymetrix SNP 10k 2.0 microarrays. The aim of this study was to develop a method to detect 
unknown small-sized amplicons. Since there was no appropriate software available for this kind of 
analysis, we had to develop a new bioinformatics analysis procedure. Novel promising candidate gene 
amplifications would then be verified and validated using the FISH technique on breast cancer TMAs. 
The statistical analysis of these data would help us to elucidate the role of the newly detected 
amplifications in breast cancer. If the amplified candidate gene is unknown in breast cancer, functional 
analysis of this gene would help to determine its possible role in breast cancer development. 
 
Finally, we intended to establish the relatively new technology of the reverse phase protein 
microarrays, in order to evaluate if its application would help us to circumvent the limitations of the 
tissue microarrays. This part of the work is shown in the Appendix. 
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2. Results 
2.1. Part A: Tissue microarrays for comparing molecular features with 
proliferation activity in breast cancer (publication) 
Published article: Int. J. Cancer: 118, 2190-2194 (2006) 
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2.2. Part B: Screening for new amplifications in breast cancer 
2.2.1. Overview of the project 
This study was based on 30 frozen breast cancer tissue samples from patients from the University 
Hospital in Basel. Extracted DNA was applied on the Affymetrix SNP 10k 2.0 arrays in order to detect 
new amplified chromosomal regions in breast cancer. In combination with the RNA expression 
profiles from the Affymetrix HG-U133A2 arrays, amplified genes, which also showed a high RNA 
expression, were chosen as candidate genes. 
A) Determination of candidate genes
B) Verification and validation of candidate genes
30 breast 
cancer tissue 
samples
DNA
RNA
Affymetrix 
SNP 10k 2.0
Affymetrix 
HG-U133A2
Candidate
genes
Amplified 
Regions
Candidate
genes
Verification 
on TMAs
Validation 
on TMAs
Cell Line 
TMA
Functional 
Analysis
 
Figure 6. Overview of the project. A) shows the road to the candidate genes. B) shows an overview of 
the process of verification and validation. 
 
For verification of the amplification status of the candidate genes, fluorescence in-situ hybridization 
was applied on two small-sized TMAs. These two TMAs (BreVer64 TMA and Breast AMPTest 
TMA) comprise the samples from the same breast cancer tissues as used for the hybridization of the 
Affymetrix arrays. The Breast AMPTest TMA contains additional 141 breast cancers and 57 normal 
breast samples. An overview of the composition of these two TMAs used for verification is shown in 
Figure 7. After successful verification, the FISH probes were applied on the Breast Prognosis TMA to 
investigate a potential correlation with survival and other clinicopathological features in breast cancer. 
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Additionally, screening of the cell line TMA, a tissue microarray containing 120 different tumor cell 
lines, was planned for the detection of cell lines, which carry the same amplification. 
A) B)
 
Figure 7. H&E stainings of verification-TMAs constructed in collaboration with the University 
Medical Center in Hamburg-Eppendorf. A) shows the BreVer64, a very small TMA containing the 30 
breast cancer samples used for the hybridization of the Affymetrix arrays. Some breast cancers are 
represented by two or three cores from different regions of the same tumor. B) shows the Breast 
AMPTest TMA, comprising the 30 breast cancers from Basel (gray quadrant) and additional 141 
breast cancer (green quadrant) and 57 normal breast samples (blue quadrant) from Hamburg. 
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2.2.2. Discovery of unrecognized amplified regions through development of a 
novel analysis procedure 
 
2.2.2.1. Analysis of the breast cancer data set with known methods 
The standard analysis method recommended by Affymetrix for the analysis of their SNP 10k 2.0 
arrays in order to determine DNA copy numbers, is based on the use of their software Chromosome 
Copy Number Analysis Tool (CNAT) (Huang et al., 2004). This analysis method uses a set of 110 
normal ethnically diverse individuals as reference. Each array to be analyzed is compared to this 
reference set leading to a copy number designation for each SNP on the array. When we performed 
this kind of analysis on the breast cancer data set described above, unfortunately, the generated results 
were not as hoped for. Neither known amplifications nor deletions were found using this method. As 
an example, the output of this analysis method (CNAT) for the chromosome 10 of the sample 02 is 
visualized in Figure 8A. In order to exclude the possibility that the weak results are due to the 
visualization method given by the CNAT, we used the DNAcopy package (Venkatraman & Olshen, 
2004) from the Bioconductor suite of R to visualize the copy number data calculated by CNAT. The 
DNAcopy package had been developed once for the analysis of aCGH arrays. After importing copy 
number data, segments with similar DNA content were calculated and visualized (Figure 8B-C, red 
lines). The results achieved with this package were slightly better than the results from the CNAT 
visualization (Figure 8B). This became possible because of the incorporated smoothing function which 
led to a slight reduction of the noise. Having realized this, we suspected that not the visualization 
method, but the procedure of the calculation of the copy number data was the weak point of the 
analysis method used until now. This means, that the use of the Affymetrix reference set may not be 
the best choice. In order to circumvent this problem, we developed an analysis method which is not 
dependent on an external reference set. The method is explained in the next section, but as an outlook, 
Figure 8C shows the result of the above analyzed chromosome with the newly developed method. 
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2.2.2.2. Our new analysis procedure 
Due to our suspicion that a comparison with external data would bias the calculation of the DNA copy 
numbers, we decided not to use the reference set provided by Affymetrix. We imported our complete 
data set into the DChip software (Li & Hung Wong, 2001; Li & Wong, 2001) and used a 
normalization procedure as recommended for Affymetrix RNA expression arrays (e.g. HG-U133A). In 
order to reduce the noise, we smoothened our data by applying our own algorithm, as summarized in 
Figure 9B. In contrast to other methods (e.g. CNAT), only signals from arrays belonging to the same 
set were used for calculation of the final DNA copy number, but no signals from external array sets 
were involved. The visualization of the DNA copy numbers along the chromosome was still done with 
the DNAcopy package. An example of the improvement of our data analysis was seen in Figure 8. The 
analyzed chromosome 10 in Figure 8C did not only have less noise than the ones in Figure 8A and 8B, 
but a small deletion of 1.2Mb became detectable. This deletion was previously masked by the noise 
created by the involvement of the external reference data set. 
Figure 8. Overview of DNA copy number data of 
chromosome 10 of sample 02 using different 
analysis methods. From left to right: p-arm to q-
arm. A) Calculation and visualization using 
Affymetrix' CNAT. B) Calculation using CNAT, 
visualization using the DNAcopy package. C) The 
analysis using our new analysis procedure (see next 
section) leads to the detection of a small deletion of 
1.2 Mb, which comprises the PTEN gene (red 
arrow).  
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Figure 9. Newly developed analysis procedure. A) shows an overview of the procedure. B) shows the 
steps of the algorithm used for calculation of the ratio. 
 
Evidence, that the karyograms detected by our analysis procedure are correct, is provided by the 
findings showing the detection of several already known amplifications and deletions in breast cancer. 
For example, the PTEN deletion (Kurose et al., 2001) in Figure 8C, the 13q13-14 deletion (Sabbir et 
al., 2006), which involves the Rb1 gene (Figure 10A), a small amplicon at 8p11-12 (Garcia et al., 
2005) (Figure 10B and 10C), a known 17q22-23 amplification (Barlund et al., 1997) (Figure 10D and 
10E) and the isochromosome 8 resulting in a 8q Loss / 8q Gain pattern (Figure 10F). 
RESULTS: Project overview 
 
 41
E
B
FD
A C
p
q
 
Figure 10. Known chromosomal aberrations found in our breast cancer data set. A)13q13-14 deletion 
in sample 27. B) 8p11-12 amplification in sample 09. C) 8p11-12 amplification in sample 17. D) 
17q22-23 amplification in sample 05. E) 17q22-23 amplification in sample 16. F) 8p loss / 8q gain in 
sample 07. 
 
2.2.2.3. New analysis method leads to the discovery of unrecognized amplifications in breast cancer 
Several amplified regions were found in our breast cancer data set. Most of them were known ones 
(Figure 10) or were localized in regions devoid of genes. These kinds of amplifications were not 
further investigated. Our priority was clearly directed towards amplifications, which were found by 
our novel analysis method in at least two samples of our data set, but had never been described before 
in breast cancer (for example amplifications in 9p24, 10q22, 12p11; Figure 11A-C). Besides these, we 
also found amplified regions, which had been described once in the literature, but were never further 
investigated in breast cancer (6q25 amplification; Figure 11D). 
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Figure 11. Interesting amplified regions found in our breast cancer data set. A) 9p24 amplification. B) 
10q22 amplification. C) 12p11 amplification. D) 6q25 amplification. See text for further explanation. 
 
9p24 (Figure 11A): Our analysis revealed two samples with an amplification of the 9p24 region. The 
only gene in the overlapping region was the nuclear factor 1 B gene (NFIB). FISH analysis on the 
BreVer64 TMA with a probe directed against this gene confirmed the amplifications. Further FISH 
analysis of the 141 Breast samples on the Breast AMPTest TMA from Hamburg revealed a 5% 
amplification rate. This gene was further investigated (see section 2.2.4). 
10q22 (Figure 11B): Amplification of this region has been reported several times in prostate cancer. 
This is the first time that this amplification was found in breast cancer. The amplification was verified 
by FISH against the KCNMA1 gene (potassium large conductance calcium-activated channel, 
subfamily M, alpha member 1) localized in the core of the amplified region. Further analysis of this 
amplification was not performed, since additional analysis of the 141 breast cancer samples on the 
Breast AMPTest TMA revealed no further case of amplification.  
12p11 (Figure 11C): Two samples from our set showed an amplification of this region. The region 
comprised the JARID1A gene (Jumonji, AT rich interactive domain 1A), which has been suggested to 
function as a repressor of differentiation, in the absence of normal pRb protein. FISH analysis 
confirmed the amplification in the two samples, but again, further analysis of this gene was not 
performed, since additional FISH analysis did not reveal any further amplified samples on the Breast 
AMPTest TMA. 
6q25 (Figure 11D): Our analysis revealed amplification of the 6q25 region in two samples. The 
overlapping amplified regions comprised only the estrogen receptor alpha gene (ESR1). This data was 
verified using a FISH probe on the BreVer64 TMA. Analysis of the Breast AMPTest TMA showed an 
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overall amplification rate of more than 25%. Due to this high rate and the importance of this gene in 
breast cancer, it was further investigated (see next section). 
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2.2.3. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast 
cancer and predicts response to tamoxifen (manuscript) 
Article resubmitted to Nature Genetics. 
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Abstract 
 
To search for previously undetected biologically important gene amplifications in breast cancers we 
used 10k Affymetrix DNA arrays. In one of 22 cancers we found a 6q25.1 amplification that involved 
only 8 SNPs, all located within one gene: Estrogen receptor alpha (ESR1). The subsequent analysis of 
more than 2000 clinical breast cancer samples revealed ESR1 amplification in 20.6% and lower level 
ESR1 copy number increases (ESR1 gains) in 15% of cancers. ESR1 amplified cancers showed 
estrogen receptor protein overexpression in 99% as compared to 66.6% of non-amplified cancers 
(p<0.0001). Within the group of estrogen receptor positive breast cancers, ESR1 amplification was an 
independent predictor of response to adjuvant anti-hormonal therapy. In a subset of 261 patients who 
had received adjuvant tamoxifen monotherapy, survival in women with ESR1 amplified cancers was 
significantly longer than in women with non-amplified estrogen receptor expressing cancers 
(p=0.023). Remarkably, ESR1 amplification was also found in a multitude of benign and precancerous 
breast diseases, suggesting that ESR1 amplification may be a very early – if not the first – genetic 
alteration in a large subset of breast cancers. 
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Introduction 
 
Breast cancer is the leading malignancy in women, accounting for more than 350.000 deaths per year 
worldwide 1. Several molecular pathways are known to play a role in breast cancer development and 
progression. Perhaps the most important pathway involves estrogen receptor alpha protein (ER). 
Binding of estrogen to ER causes phosphorylation and dimerization of the receptor that acts as a 
transcriptional promoter conferring a growth signal to breast epithelial cells 2. This makes ER one of 
the most important therapeutic targets in breast cancer 3. More than two thirds of breast cancers show 
expression of ER at the time of diagnosis 4, and immunohistochemical detection of ER expression is 
routinely used for decision making for hormonal (anti-ER) therapy of breast cancer 5. Current anti ER 
treatment strategies include blocking by selective modulators (SERMs, e.g. Tamoxifen, Raloxifen), 
destabilization and degradation of ER by selective downregulators (SERDs, e.g. Fulvestrant) or 
disruption of estrogen synthesis (aromatase inhibitors, e.g. Anastozole, Letrozole, Exemestan) which 
results in a significant decrease of tumor growth in about 30-50% of patients 6. 
 
Gene copy number increase (amplification) is a major mechanism for cancer cells to boost the 
expression of gene products that provide them with a growth or survival advantage. Numerous genes 
have been found amplified in a fraction of breast cancers including HER2 at 17q21 7, CMYC at 8q24 
8, EGFR at 7p12 9, AIB1 at 20q13 10, or CCND1 at 11q13 11. The example of HER2 also shows that 
amplified genes may be particularly suited as therapeutic targets. Trastuzumab (Herceptin) is highly 
effective in the treatment of HER2 amplified/overexpressing breast cancers 12,13. Several lines of 
evidence suggest that various genes that can give a growth advantage to breast epithelial cells through 
amplification are still not discovered. First, amplicons usually span several megabases of genomic 
distance and harbor numerous genes. This makes it difficult to determine which gene(s) drive 
amplification. Second, amplifications may be very small and therefore difficult to detect by classical 
amplification screening methods 14. In this project we used a three-step approach to search for 
previously undetected, clinically relevant gene amplifications in breast cancer. First, we used a DNA 
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microarray approach (Affymetrix 10k mapping array) to screen for gene copy number changes in 22 
high-grade breast cancers. Second, we specifically filtered these DNA copy number data for small size 
amplifications of potentially relevant gene classes. Then we used fluorescence in situ hybridization 
(FISH) to validate identified amplifications and to screen for their clinical relevance on a tissue 
microarray (TMA) containing samples from more than 2,000 breast cancer patients with clinical 
follow up data 15. Stunningly, this approach exposed amplification of the ESR1 gene encoding 
estrogen receptor alpha (ER) as a key mechanism in breast cancer development. 
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Results 
 
DNA Chip analysis. We used Affymetrix 10k SNP chips to search for genomic loci harboring gene 
amplifications in breast cancer. Because most gene amplifications are linked to high-grade cancers, we 
selected 22 grade 3 breast cancers (according to Bloom, Richardson and Ellis 16) for analysis. Among 
several other amplifications (data not shown), we found 2 samples (9%) with amplification at 
chromosome 6q25.1. One of these tumors had a very narrow region of amplification at 6q25.1 that 
was detectable on 8 SNPs and spanned 514Kb (base positions 152.025.289- 152.539.833). The 
estrogen receptor alpha encoding gene ESR1 was the only gene inside this area (figure 1). This 
observation raised the possibility, that gene amplification might be a previously unrecognized key 
mechanism for overexpression of this critical breast cancer gene. 
 
ESR1 amplification in breast cancer. To investigate the possible importance of our observation, we 
analyzed an existing breast cancer tissue microarray (TMA) containing more than 2,000 breast cancers 
15. For fluorescence in situ hybridization (FISH) analysis we prepared a probe from BAC RP11-
450E24 located inside the ESR1 gene. FISH analysis of ESR1 was successful in 1739/2197 (79%) 
arrayed breast cancer tissues. No results could be obtained from 458 cases, either due to lack of tumor 
cells in the tissue spot, complete loss of tissue spots, or insufficient hybridization. We defined the 
threshold for ESR1 amplification according to the generally accepted scoring system used for HER2 
amplification evaluation in FDA approved test kits (PathVysion, Abbott, IL). ESR1 amplification was 
assumed if at least two times more ESR1 signals than centromere 6 (cen 6) signals were present (ratio 
ESR1/cen6 ≥2.0). Tissue samples with an ESR1/cen 6 ratio larger than 1.0 but less than 2.0 (1.0 < 
ratio ESR1/cen6 < 2.0) were classified as „ESR1 gains“. All other tissues (ratio ESR1/cen6 ≤ 1.0) 
were considered normal. According to these criteria, we found ESR1 amplification in 358/1739 
(20.6%) analyzable tissue samples. ESR1 copy number gains were present in another 266 (15.3%) of 
tumors. Examples of amplified and non-amplified cancer cells are shown in figure 2. Most amplified 
tumors showed a clustered arrangement of additional ESR1 copies indicating intrachromosomal 
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amplification type (homogeneously staining regions), and had moderate absolute copy numbers 
ranging between 6 and 9 copies. Only 18% of amplified cases had 10 or more ESR1 gene copies per 
cell. We next studied the relationship between ESR1 copy number changes and breast cancer 
phenotype (table 1). ESR1 amplifications and gains were significantly associated with low-grade 
tumors (p<0.0001) and absence of lymph node metastases (p<0.05). This finding was unexpected, 
because gene amplifications are usually linked to high grade and advanced cancers 9. The frequency of 
ESR1 amplification varied considerably between cancers of different histological subtypes. For 
example, medullary cancers, which are characterized by a high-grade phenotype, had a particularly 
low fraction of amplified tumors (2.0%), whereas mucinous cancers that are mostly low-grade had 
particularly high rates of ESR1 amplifications (35.6%).  
 
ESR1 amplification in non-malignant and premalignant breast. Because of the association of 
ESR1 amplification with low malignancy cancer phenotypes, we expanded our analysis to a series of 
non-malignant and preneoplastic tissues. Most remarkably, ESR1 amplification was also frequently 
found in several of these tissues (table 2). A particularly high frequency of ESR1 amplification was 
seen in benign papillomas (8/22, 36%), but amplification was also present in usual ductal hyperplasias 
(1/12, 8.3%). These findings suggested that ESR1 amplifications may play a key role in a distinct 
molecular “road to breast cancer” characterized by particularly high levels of estrogen receptor alpha 
expression. 
 
Impact on estrogen receptor alpha protein expression levels. To investigate the impact of ESR1 
amplification on ER protein levels we next compared ESR1 gene copy numbers to 
immunohistochemical ER protein expression levels. IHC analysis was successful in 2018/2197 (92%) 
breast cancers (table 1). As expected, ESR1 amplification was tightly linked to ER protein expression 
(p<0.0001, table 3). Virtually all cases with increased ESR1 gene copy numbers (amplifications and 
gains) had high-level expression. Among 341 breast cancers with ESR1 amplification, 339 (99%) had 
detectable ER expression. The vast majority of these tumors (94%) had the highest ER scores (7-8) 
according to Allred 17 . This was also true for tumors exhibiting ESR1 gains where 89% of samples 
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showed strong (score 7-8) ER expression. However, the data also showed that ESR1 amplifications or 
gains were not the sole reason for high-level ER expression. Almost half (46%) of strong (score 7-8) 
ER expressors had no ESR1 gene copy number alterations. Given the paramount role of gene 
amplification for response to other targeted therapies, this result raised the question of whether ESR1 
amplified breast cancers might respond differently to anti-hormonal therapies than non-amplified 
overexpressors.  
 
ESR1 amplification and response to tamoxifen. To determine the predicitive impact of ESR1 gene 
amplification on response to hormonal treatment, we analyzed a subgroup of 261 patients that had 
previously undergone adjuvant monotherapy with tamoxifen. For this analysis, we stratified the 
patients into three groups: I) ER IHC negative cancers (Allred scores 0-2), II) ER IHC positive cancers 
(Allred scores 3-8) lacking ESR1 amplification, and III) ESR1 amplified cancers. It showed that ESR1 
amplified cancers are indeed highly responsive to tamoxifen (Figure 3). As expected, the combined 
DNA/protein analysis revealed the worst survival in IHC negative cancers (figure 3a). However, 
patient survival was significantly better in the ESR1 amplified population as compared to patients with 
non amplified ER positive cancers (p=0.0233; ESR1 amplification versus ER positive in figure 3a). To 
exclude a potential survival bias caused by classical prognostic factors of breast cancer we performed 
a multivariate analysis (Cox proportional hazards) including ER expression, tumor grade, pT and pN 
categories. We found that the prognostic value of ESR1 amplification in tamoxifen treated patients 
was independent of these factors (table 4). Stunningly, the prognostic impact of ESR1 amplification 
was even retained in the subgroup of cancers with strongest ER expression (figure 3b; ESR1 
amplification versus ER 7-8, p=0.0889). Furthermore, response to tamoxifen was also dependent on 
the absolute ESR1 copy number (figure 3c). 
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Discussion 
 
In this project, a “FISHing expedition” was necessary to discover that the most frequently analyzed 
and - on the protein level – best-characterized gene in breast cancer (more than 30,000 Medline entries 
so far) is a common subject of gene amplification. Although only one small tissue sample (0.6mm 
diameter) was analyzed per tumor, ESR1 amplification was detected in 20.6 % of breast cancers. 
Using the same breast cancer TMA and the same definition of amplification, we previously found 
amplifications of CCND1 in 20.1%, HER2 in 17.3%, MDM2 in 5.7%, CMYC in 5.3%, and EGFR in 
0.8% of the tumors 9. Given the critical role of estrogen receptor expression for breast cancer therapy 
and the well-known importance of gene amplification for drug target overexpression, it is remarkable 
that the critical relevance of ESR1 amplification has not been discovered earlier. To a large extent, the 
difficulties detecting the 6q25.1 amplicon appear to be caused by the generally small size of the 
amplicon. Preliminary mapping experiments suggest that the amplicon measures less than 1 megabase 
in the majority of cases (data not shown). In our DNA microarray analysis, amplification was detected 
only in two cases, including one tumor where the amplicon was limited to an approx. 514Kb sequence 
harboring only the ESR1 gene. Such single gene amplicons are difficult to identify even with high-
resolution CGH arrays. Only one matrix CGH study had previously – together with 30 other 
amplicons - described a 6q25.1 amplification containing ESR1 in 3 of 31 analyzed breast cancers 18. 
Because the experimental noise is often considerable in array hybridization experiments, single spot 
peaks are frequently seen and artifacts are difficult to distinguish from true amplification events.  
 
The availability of large, well-characterized TMAs allowed us to extensively study the epidemiology 
of ESR1 amplifications. The striking association with positive ER IHC – 99% of our amplified cases 
were also found positive by IHC – and the ER expression levels not only validated our experimental 
approach but also demonstrated a strong functional importance of ESR1 gene amplification. 
Apparently, ESR1 amplification or gain is present in a subset of about 50% highly ER expressing 
breast cancers. This observation was interesting in the light of the striking association of other gene 
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amplifications with response to biological drugs targeting the specific gene products. Notably, 
amplification of HER2, EGFR and also TOP2A was always more predictive for response to therapy 
than protein overexpression detected by IHC 19-23. The superior predictive role of gene amplification 
may partly be due to inherent technical issues of IHC as immunostaining is subject to tissue processing 
variability and not linearly related to the protein quantity. On the other hand, gene amplification is a 
result of complex selection processes, and it is tempting to speculate that genes that have undergone 
amplification in a particular cell clone may be critically important for cell growth and survival in this 
clone and thus represent the Achilles tendon for targeted therapy.  
 
The availability of 261 breast cancers from patients who had undergone adjuvant anti-ER 
monotherapy with tamoxifen allowed us to investigate the possible impact of ESR1 amplification on 
response to anti-hormonal therapy. Despite of the small size of this cohort, the retrospective nature of 
data collection, and the potentially variable duration of tamoxifen therapy, a marked survival 
difference became apparent between ESR1 amplified and ESR1 non-amplified IHC positive tumors. 
Remarkably, this association was independent of grade, stage, and pN status in our multivariate 
analysis. Altogether, these data strongly suggest that ESR1 amplification may identify a subgroup of 
ER positive breast cancers with a particularly high likelihood to positively response to anti-estrogen 
therapy. This result could not completely be expected, because an opposite mechanism is well known 
to occur in prostate cancer. In this tumor type, amplification of the androgen receptor does not occur in 
untreated primary tumors but develops in about 20-30% of cases under anti hormonal therapy and 
causes resistance to further anti-hormonal therapy 24-26. 
The high frequency of ESR1 amplification in low grade and early stage breast cancer together with the 
critical role of ER for proliferation control in breast epithelium would be well consistent with a very 
early – if not initializing – role of ER amplification for a subset of breast cancers. To investigate the 
role of ESR1 amplification in premalignant proliferative breast lesions another set of breast lesions 
including non-neoplastic and precancerous tissues was analyzed for ESR1 amplification. The 
observation of frequent and often high level ESR1 amplifications not only in carcinoma in situ but as 
well in papillomas (36%) and usual ductal hyperplasias (8%) was striking. Gene amplification has so 
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far never been demonstrated in benign breast lesions. These findings suggest that ESR1 amplification 
is not a hallmark for invasive breast cancer but may represent a key mechanism for development of 
various types of proliferative breast disease. As gene amplification is thought to be non-reversible, it is 
tempting to speculate that ER amplification may constitute a decisive mechanism for initiation of 
neoplastic (clonal) breast disease. It appears possible that presence of ESR1 amplification may 
therefore be indicative of proliferative breast disease with increased potential for malignant 
transformation. This hypothesis would be consistent with previous IHC studies suggesting a possible 
link between high-level ER expression in benign proliferative breast disease and an increased risk for 
breast cancer development 27,28. It is thus possible, that ESR1 amplification status represents a useful 
prognostic marker in patients with benign appearing proliferative breast lesions. 
 
In summary, our data suggest that ESR1 amplification is a frequent event in proliferating breast 
disease and breast cancer. ESR1 amplification defines a subtype of primary breast cancers that 
optimally benefits from anti hormonal therapy.  
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Materials and Methods 
 
Tissues. For DNA Chip analysis experiments, 22 fresh frozen grade 3 breast cancer samples were 
selected from the frozen tissue archive of the Institute of Pathology, University Hospital Basel, 
Switzerland. For epidemiological evaluation of ESR1 amplifications, our existing Breast Prognosis 
TMA containing more than 2000 breast tissues was analyzed. The composition of this TMA has been 
described before 15. The patho-histological and clinical data of these tissues are summarized in table 1. 
The type of adjuvant treatment was known for 420 patients. A subset of 261 patients received 
hormonal treatment with tamoxifen (5 years was standard, but detailed information was not available) 
but no adjuvant cytotoxic chemotherapy. The patients were treated and evaluated at the University 
Hospital in Basel (Switzerland), the Womens’ Hospital Rheinfelden (Germany), and the 
Kreiskrankenhaus Lörrach (Germany) between 1985 and 2000. The patients’ attending physicians 
were contacted to collect follow up data. The median observation time was 60 months (range 2-138). 
Staging variables were collected from the patient files. In addition, a second TMA containing 50 
normal breast samples and 186 non-neoplastic and premalignant breast lesions was analyzed. This 
TMA included 62 DCIS, 10 LCIS (lobular neoplasias), 14 apocrine metaplasias, 27 usual ductal 
hyperplasias, 5 atypical ductal hyperplasias, 22 cases of fibrocystic disease, 31 papillomas, and 15 
cases of sclerosing adenosis. 
 
DNA Chip analysis. DNA was extracted from three punched tissue cylinders (diameter 0.6 mm) from 
each of the 30 fresh frozen tumor samples according to the manufacturer’s instructions of the QIAmp 
DNA Mini Kit (Qiagen, Hilden, Germany). DNA was further processed as described in the GeneChip 
Mapping 10K 2.0 Assay Manual (Affymetrix, Santa Clara, CA). Briefly, 250ng of the DNA was 
digested with the XBA I restriction enzyme, ligated to an adaptor and amplified by PCR. The resulting 
PCR products were fragmented, end-labeled and hybridized to the GeneChip Human Mapping 10K 
Array Xba 142 2.0. After hybridization, the microarray chip was washed and stained on an Affymetrix 
fluidics station. The chips were scanned using the Affymetrix GeneChip scanner 3000. 
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Data Acquisition and Analysis. Raw data from the scanned arrays was acquired using the GeneChip 
Operating Software (Affymetrix). Quality of the data was checked as described in the GeneChip 
Mapping 10K 2.0 Assay Manual (Affymetrix). Only 22 of the samples passed these quality controls 
and were used for further data analysis. The data files were imported into the DChip software 29, and 
pre-processing and normalization were performed as described in the user manual. The resulting signal 
intensities were imported into the R suite 30. Data were further processed with a home made analysis 
tool using all measurements between the 25th and 75th percentile as a reference for each DNA spot 
(code available upon request, C. Ruiz). Data were then modified to fit the input requirements of the 
DNAcopy package 31 of the Bioconductor suite 32. The DNAcopy package was used to calculate and 
visualize segments with similar DNA content. Segments with higher DNA content than the above 
calculated reference were classified as candidate regions for gene amplification. 
 
Fluorescence in situ hybridization (FISH). TMA sections were treated according to the Paraffin 
Pretreatment Reagent Kit protocol (Vysis, Downers Grove, IL) before hybridization. FISH was 
performed with a digoxigenated BAC probe (BAC RP11-450E24, RZPD, Germany) containing the 
ESR1 gene and a Spectrum-Orange labeled chromosome 6 centromeric probe (CEP6) as a reference 
(purchased from Vysis). Hybridization and posthybridization washes were according to the ‘LSI 
procedure’ (Vysis). Probe visualization using fluorescent isothiocyanate (FITC)-conjugated sheep 
anti-digoxigenin (Roche Diagnostics, Rotkreuz, Switzerland) was as described 33. Slides were 
counterstained with 125 ng/ml 4’,6-diamino-2-phenylindole in an antifade solution. Hybridization and 
posthybridization washes were according to the ‘LSI procedure’ (Vysis). Slides were then 
counterstained with 125 ng/ml 4’,6-diamino-2-phenylindole in an antifade solution.  
 
Immunohistochemistry. Immunohistochemical detection of ER alpha protein was performed using 
antibody NCL-L-ER-6F11 (Novocastra, Newcastle, UK). In brief, slides were deparaffinized and 
incubated in a pressure cooker at 120°C for 12 min in pH6 citrate buffer (Retrievit 6 #BS-1006-00, 
BioGenex, San Ramon, CA). After blocking of endogeneous peroxidase, prediluted (1:1000) primary 
antibody was applied and the slides were incubated overnight at 4°C. The Vectastain ABC Elite 
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system was used for detection of antibody binding. IHC scoring was performed according to the 
Allred score 17. In brief, ER staining intensity was recorded in a 4-step scale (0-3) and the fraction of 
ER positive tumor cells in a 5-step 1-5) scale. Combination of both parameters results in an 8-step 
score, where all samples with score >2 are regarded as ER positive. 
 
Statistics. Contingency table analysis and Chi-square tests were used to study the relationship between 
histological tumor type, grade, stage and gene amplification. Survival curves were plotted according to 
Kaplan-Meier. A log rank test was applied to examine the relationship between gene amplifications 
and patient survival. Cox regression analysis was performed to test for interdependencies between 
analyzed variables in their relation with patient survival. 
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Tables and Figures: 
 
Table 1. Relationship between ESR1 copy number changes and invasive breast cancer phenotype 
   ESR1 FISH result  ER IHC result 
  on array (n) analyzable (n) amplification gain p  analyzable (n) positive* p 
Cancers all 2197 1739 20.6% 15.3%   2018 76.6%  
Histology ductal carcinoma 1552 1207 21.5% 16.0%   1429 77.1%  
 lobular carcinoma 312 207 19.3% 13.8%   275 87.6%  
 mucinous carcinoma 69 37 35.6% 24.4% 0.0337**  61 93.4% <0.0001** 
 medullary carcinoma 58 48 2.0% 2.0% <0.0001**  52 17.3% <0.0001** 
 tubular carcinoma 56 42 18.6% 14.0%   48 89.6%  
 cribriform carcinoma 65 55 29.8% 12.3%   56 91.1%  
 papillary carcinoma 30 27 19.2% 15.4%   28 67.9%  
 others* 79 56 4.9% 14.8%   69 34.8%  
pT stage pT1 820 578 22.3% 15.6% 0.7295  716 80.4% 0.0020 
 pT2 1023 811 19.7% 14.8%   948 73.2%  
 pT3 124 92 18.8% 13.5%   114 72.8%  
 pT4 242 189 17.8% 16.8%   229 80.3%  
Nodal stage pN0 950 711 22.3% 14.4% 0.0422  849 78.1% 0.1765 
 pN1 793 608 16.5% 16.5%   726 75.6%  
 pN2 121 90 14.8% 12.5%   113 70.8%  
BRE grade G1 545 421 25.6% 15.2% <0.0001  522 92.9% <0.0001 
 G2 844 685 21.6% 18.5%   833 86.3%  
  G3 655 571 15.0% 11.7%   661 51.9%  
* according to Allred score;           
** versus ductal carcinoma          
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Table 2. Prevalence of ESR1 copy number changes in normal and premalignant breast tissues 
 
 
 
 
Table 3. Comparison of ER amplification and expression 
ESR1 FISH result  ER IHC result (Allred score) 
 n  0-2 (%) 3-4 (%) 5-6 (%) 7-8 (%) 
normal 1056  33.3 8.2 14.1 44.3 
gain 255  2.4 1.6 7.5 88.6 
amp 341  0.6 0.3 4.7 94.4 
 
 
 
ESR1 FISH result 
Histology  on array (n) analyzable (n)  
amplification (%) gain (%) 
normal breast tissue 50 21 0.0 0.0 
fibrocystic disease 22 13 0.0 7.7 
apocrine metaplasia 14 4 0.0 0.0 
usual ductal hyperplasia 27 12 8.3 25.0 
atypical ductal hyperplasia 5 1 0.0 100.0 
sclerosing adenosis 15 8 0.0 0.0 
papilloma 31 22 36.4 4.5 
DCIS 62 40 35.0 7.5 
LCIS (lobular neoplasia) 10 3 33.3 33.3 
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Table 4. Contribution of potential prognostic factors to tumor specific survival in breast cancer 
patients that received Tamoxifen monotherapy (multivariate COX regression model) 
 
Parameter  p-value
pT stage pT1-4 0.3867
BRE grade G1-3 0.1568
pN stage pN0-pN2 <0.0001
ER expression status neg/pos (Allred score) 0.0003
ESR1 amplification status Normal vs amplified/gained 0.0080
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Figure 1. Position of the 6q25.1 amplicon spanning 1.2Mb between base positions 151.538.830 and 152.729.709. The blue and green bar indicates localization of 
the amplified regions identified in two breast cancer samples BD12 and BD25.  
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Figure 2. ESR1 FISH analysis in breast cancer. 
 
a) Cell nuclei showing clouds of green ESR1 gene copies indicating intrachromosomal ESR1 
amplification. Red signals represent centromere 6. Insert: Higher magnification of a cell nucleus 
showing 2 red centromere 6 signals and >10 green ESR1 signals. 
 
b) Nuclei with normal ESR1 copy number (2 green ESR1 signals and 2 red centromere 6 signals 
per cell nuclei). 
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Figure 3. Impact of ESR1 amplification (defined as ESR1 gene to Cen6 copy number ratio ≥2.0) and 
expression on prognosis in patient that received Tamoxifen monotherapy. a) Immunohistochemistry 
results grouped into ER negative (scores 0-2) and ER positive (scores 3-8, no ESR1 amplification) 
according to Allred as compared to ESR1 amplification. b) Immunohistochemistry results by Allred 
scores versus ESR1 amplification. c) Impact of the ESR1 copy number on patient survival. 
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2.2.4. Nuclear Factor 1 B (NFIB) as target gene of the 9p24 amplification in 
human breast cancer (manuscript) 
Manuscript in preparation. 
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Abstract 
 
Gene amplification is a common mechanism in cancer to overexpress potential oncogenes. Several 
amplifications with impact on prognosis have already been described in breast cancer. Using 
Affymetrix SNP Chip technology, we screened 30 human high grade breast cancers for new small-
sized amplifications. We identified two cancers with a 9p24 amplification. One of these two amplicons 
spanned a small region of 0.8 Mb, comprising only the Nuclear Factor 1 B gene (NFIB). Fluorescence 
in situ hybridization (FISH) analysis of this gene was applied on a tissue microarray (TMA) 
containing more than 2000 breast tumors. NFIB gene amplification was found in 5% of all breast 
cancers analyzed, but with an increased amplification rate of 19% in medullary carcinomas (p = 
0.0007). Amplification was correlated with high grade (p < 0.0001) and high Ki67 proliferation index 
(p < 0.0001). NFIB gene silencing using RNA interference technology in three cell lines expressing 
this protein led to a reduction in proliferation. This suggests that NFIB stimulates proliferation. 
Analysis of a breast cancer data set from a public repository (GSE 1456) revealed higher levels of 
NFIB expression in breast tumors belonging to the subgroup of breast cancers with a basal-like 
expression. Taken together these findings suggest an important role of NFIB in breast cancer 
development. 
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Introduction 
 
The nuclear factor I (NFI) proteins belong to a family of sequence specific DNA-binding proteins. 
They all bind as homo- and heterodimers via an amino terminal DNA-binding and dimerization 
domain to the palindromic sequence TGGC/A(N5)GCCA and with lower affinity to the half 
palindrome (Kruse & Sippel, 1994). Originally, this protein family was identified to be required for 
replication of adenovirus DNA, but in the last two decades, it has been recognized as a potent 
transcriptional regulator of many viral (Apt et al., 1993; Kumar et al., 1993; Mink et al., 1992; Plumb 
et al., 1991) and cellular genes (Cereghini et al., 1987; Rossi et al., 1988). The NFI family comprises 
four members: NFIA, NFIB, NFIC and NFIX, and expression of several isoforms through alternative 
splicing have been reported for each of these genes (reviewed in (Gronostajski, 2000)). The expression 
pattern of the four NFI genes has mainly been studied in mice. They are most highly expressed in 
lung, liver and heart, and weakly in spleen and testis (Chaudhry et al., 1997). NFIB has been suggested 
to be essential for normal lung development, since NFIB null mutant mice die early postnatally and 
display severe lung defects (Grunder et al., 2002). In man, a correlation to cancer has been suggested, 
since NFIB was found as translocation partner of the high mobility group AT-hook 2 gene (HMGA2) 
in two pleomorphic adenomas (Geurts et al., 1998) and in two lipomas (Nilsson et al., 2005) resulting 
in a fusion protein containing the last five amino acids of NFIB. In addition, the NFIB gene was also 
reported to be part of a 9p23-24 amplicon found in esophageal cancer cell lines (Yang et al., 2000). 
However, the authors suggest that GASC1, which is localized more than 7 Mb away from the NFIB 
gene locus, as the major tumor promoting candidate gene of that amplicon. Recently, Zhou et al (Zhou 
et al., 2006) reported gains on DNA level of the NFIB gene when inactivating p53 and Rb in the 
prostate epithelium of the mouse. 
 
Gene amplification is a common mechanism for cancer cells to increase the expression levels of 
proteins that can provide them with a growth or survival advantage. Breast cancer as the leading 
cancer cause in women is also influenced by gene amplification. Several genes have been found to be 
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amplified in a fraction of breast cancers including ERBB2 at 17q21, CMYC at 8q24, EGFR at 7p12, 
AIB1 at 20q13, or CCND1 at 11q13 (Al-Kuraya et al., 2004; Anzick et al., 1997; Pauletti et al., 1996; 
Simpson et al., 1997; Visscher et al., 1997). Recently, we were able to show amplification of the 
estrogen receptor alpha gene (ESR1) in breast cancer and its potential impact on breast cancer drug 
response (manuscript under review, Nature Genetics). For this study, we used the same approach to 
screen 30 high grad breast cancers for gene copy number changes using DNA microarrays (Affymetrix 
SNP 10k array). We focused on small-sized amplifications harboring potentially relevant gene classes. 
This procedure led to the discovery of the NFIB gene amplifications in certain breast cancers. In order 
to evaluate its relevance in breast cancer, we applied fluorescence in situ hybridization (FISH) on a 
tissue microarray (TMA) containing samples from more than 2000 breast cancer patients, and 
determined a proliferation supporting role of this protein by using RNA interference in three cell lines 
expressing NFIB. 
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Materials and Methods 
 
Tissues. For DNA and RNA chip analysis experiments, 30 fresh frozen grade 3 breast cancer samples 
were selected from the frozen tissue archive of the Institute of Pathology, University Hospital Basel, 
Switzerland. For epidemiological evaluation of NFIB amplifications, our existing Breast Prognosis 
TMA containing more than 2000 breast tissues was analyzed. The composition of this TMA has been 
described before (Ruiz et al., 2006). 
 
Affymetrix DNA SNP and Affymetrix RNA chip analysis. DNA and RNA were extracted from 
three punched tissue cylinders (diameter 0.6mm) from each of the 30 fresh frozen tumor samples 
according to the manufacturer's instructions of the QIAmp DNA Mini Kit (for DNA) and RNeasy Kit 
(for RNA) (Qiagen, Hilden Germany). DNA and RNA were further processed as described in the 
Affymetrix GeneChip Assay manuals (Affymetrix, Santa Clara, CA). After hybridization to the 
GeneChip Human Mapping 10k Array Xba 142 2.0, respectively to the GeneChip HG U133A 2.0, the 
microarray chips were washed and stained on an Affymetrix fluidics station. The chips were scanned 
using the Affymetrix GeneChip scanner 3000. 
 
Data acquisition and analysis of the Affymetrix SNP arrays. Raw data from the scanned SNP 
arrays was acquired using the GeneChip Operating Software (Affymetrix). Quality of the data was 
checked as described in the GeneChip Mapping 10K 2.0 Assay Manual (Affymetrix). Only 22 of the 
samples passed these quality controls and were used for further data analysis. The data files were 
imported into the DChip software (Li & Wong, 2001), and pre-processing and normalization were 
performed as described in the user manual. The resulting signal intensities were imported into the R 
suite (R Development Core Team, 2005). Data were further processed with a home made analysis tool 
using all measurements between the 25th and 75th percentile as a reference for each DNA spot (code 
available upon request, C. Ruiz). Data were then modified to fit the input requirements of the 
DNAcopy package (Venkatraman & Olshen, 2004) of the Bioconductor suite (Gentleman et al., 2004). 
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The DNAcopy package was used to calculate and visualize segments with similar DNA content. 
Segments with higher DNA content than the above calculated reference were classified as candidate 
regions for gene amplification. 
 
Data acquisition and analysis of the Affymetrix RNA arrays. Raw data from the scanned 
expression arrays was acquired using the GeneChip Operating Software (Affymetrix). In the case of 
the public available Swedish Breast cancer set (GSE 1456), the corresponding files were downloaded 
from the Gene Expression Omnibus (GEO) repository (Pubmed, NCBI). Data were imported into the 
Bioconductor suite and normalized by usage of the RMA algorithm (Irizarry et al., 2003) using the 
standard settings. The normalized values were filtered using the Genefilter package (Gentleman et al., 
2006) of Bioconductor. The filtered data-set was subjected to a t-test to find differential expressed 
genes. Resulting p-values were manually corrected by using Benjamini and Hochberg false discovery 
rate multiple testing (Hochberg & Benjamini, 1990). Correspondance analysis and Between Group 
Analysis were performed using the made4 package (Culhane, 2006). 
 
Fluorescence in situ hybridization (FISH). NFIB FISH analysis of the TMAs was performed with 
digoxigenated BAC probes (RP11-280O24; RZPD, Berlin, Germany) and the centromeric probe of the 
chromosome 9 (Vysis, Downers Grove, IL). Hybridization and posthybridization washes were 
according to the 'LSI procedure' (Vysis). Amplification was defined as presence of at least 2 times 
more gene copies than centromere signals. 
 
Cell culture. Cells from the different cell lines were cultured in Optimem (Invitrogen, Carlsbad, CA) 
containing 10% FCS (Amimed, Basel, Switzerland) and 1% Penicillin/Streptamycin (Amimed) in a 
humidified incubator at 37°C and 5% CO2. 
 
RNA extraction from cell lines. RNA extraction from cell lines was performed as described in the 
manufacturer's specifications of the RNeasy kit (Qiagen, Hilden, Germany) including a DNAse I 
incubation (Qiagen). RNA concentration was determined using a spectrophotometer. 
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RNA interference. NFIB specific, as well as unspecific RNAi (nsRNA, control) were purchased from 
Qiagen. Lipofectamine (Invitrogen) was used as transfection reagent according to the manufacturer's 
protocol. RNAi was applied as described in the Qiagen protocol. Briefly, siRNA transfection was 
performed in serum- and antibiotic free medium for 24 hours. After transfection, medium was replaced 
with 10% FCS containing medium. Cells were harvested at regular time points to determine NFIB 
knockdown and proliferation rate. 
 
Proliferation assay. Cells were harvested using Trypsin/EDTA (1:250) (Amimed) four days after 
addition of the siRNA. Counting of the cells was performed using the CASY cell counter 
(Schärfesystem GmbH, Reutlingen, Germany) as described in the manufacturer's handbook. Cell 
numbers were normalized to cells treated with control nsRNA. 
 
Reverse transcription and polymerase chain reaction (PCR). 2µg of total RNA was reverse 
transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics, 
Rotkreuz, Switzerland) following the manufacturer's protocol. RNA extracted from cell lines was 
reverse transcribed using Oligo-p(dT)15 primers (Roche Diagnostics). For RNA from frozen tissue, 
random hexamer primers (Roche Diagnostics) were chosen. The cDNA from the reverse transcription 
was amplified using the AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA) as 
described in the AmpliTaq protocol in the presence of 1.0µM of the appropriate primers (MWG 
Biotech AG, Ebersberg, Germany) listed below (5' → 3'). Separation of the amplification products was 
obtained by agarose gel electrophoresis (Ambion Inc, Austin, TX). 
NFIB: Exon 8 forward: 
5' – CCT CCA CCT TCA CCG TTG CCA TTT – 3' 
NFIB: Exon 9 reverse: 
5' – CCA AGC TAG CCC AGG TAC CAG GA - 3' 
NFIB: full length cDNA forward: 
5' – GCG GCT CAT GAA ATC CCC ACA – 3' 
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Real-time PCR. Different amounts of cDNA and different primer concentrations were used for 
quantitative real-time PCR using the LightCycler FastStart DNA MasterPLUS HybProbe Kit (Roche 
Diagnostics) on the LightCycler instrument (Roche Diagnostics). Normalization was done by using 
GAPDH or β–Actin concentration as control. Primers and hybridization probes used are listed below 
(TIB MOLBIOL, Berlin, Germany): 
Forward primers: 
GAPDH: 5' – GAA GGT GAA GGT CGG AGT C – 3' 
NFIB:  5' – TCA CTC AGG ATG AAT TTC ACC – 3' 
ACTB:  5' – AGC CTC GCC TTT GCC GA – 3' 
Reverse primers: 
GAPDH: 5' – GAA GAT GGT GAT GGG ATT TC – 3' 
NFIB:  5' – TGC CCA CTT CTG TTT GAT T– 3' 
ACTB:  5' – CTG GTG CCT GGG GCG – 3' 
Hybridization probes Fluorescein part: 
GAPDH: 5' – AGG GGT CAT TGA TGG CAA CAA TAT CCA –FL –3' 
NFIB:  5' – AAG CTC ATC TTT CAG TGC TCT TTC TTC –FL –3' 
ACTB:  5' – TTG CAC ATG CCG GAG CCG TTG –FL –3' 
Hybridization probes LightCycler part: 
GAPDH: 5' – LC Red640-TTT ACC AGA GTT AAA AGC AGC CCT GGT G –3' 
NFIB:  5' – LC Red640-TCC TTT GAC ATT CGC TTC TCA TGC T –3' 
ACTB:  5' – LC Red640-CGA CGA CGA GCG CGG CGA TAT C –3' 
 
Whole cell protein lysates and subcellular fractionation. Whole cell protein lysates were created by 
lysing the cells in SDS lysis buffer (50mM Tris pH 6.8, 2% SDS, 5% Glycerol, 5mM EDTA) 
including protease inhibitors (Complete Mini, Roche Diagnostics) directly on the plate. For subcellular 
fractionation two distinct buffers were used, first the cytosol fraction was extracted using a low salt 
buffer (20mM Hepes pH 7.9, 10mM KCl, 0.1mM NaVO4, 1mM EDTA, 1mM EGTA, 0.2% NP-40, 
10% Glycerol). Then, the nuclear fraction was extracted using a high salt buffer (420mM NaCl, 20mM 
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Hepes pH 7.9, 10mM KCl, 0.1mM NaVO4, 1mM EDTA, 1mM EGTA, 20% Glycerol). Both buffers 
were supplemented with protease inhibitors (Complete Mini, Roche Diagnostics). After removing the 
insoluble material by centrifugation, the lysates were shock-frozen in liquid nitrogen and stored at -
80°C. 
 
Western blot analysis. Concentration of protein lysates was determined using the RC DC Protein 
Assay (Bio-Rad Laboratories, Hercules, CA) and equal amounts of proteins (10ug or 15µg) were 
resolved by usage of 4-20% precast Tris-glycine gels  (Invitrogen) and transferred to Immobilon-P 
(Millipore) membranes. Membranes were blocked with 5% blocking solution (5% dry, non-fat skim 
milk powder in PBS) overnight at 4°C. Incubation with the rabbit polyclonal anti-NFIB antibody 
(ABCAM, Cambridge, UK) was done for 2 hours at room temperature; Incubation with Anti-GAPDH 
antibody (ABCAM) for one hour. Detection was performed with an anti-rabbit or an anti-mouse 
horseradish peroxidise (HRP)-conjugated secondary antibody (Jackson Immunoresearch, West 
Baltimore, PA) by enhanced chemiluminescence (ECL and ECL Plus, Amersham). 
 
Cell line TMA. Cells were cultured as described until ten 75cm2 plates were 70-80% confluent. Cells 
were harvested, washed and centrifuged. The cell pellet was fixed in formalin for 24 hours and then 
placed into a Cytoblock cassette (Thermo Shandon GmbH, Frankfurt, Germany) and further processed 
as described in the Cytoblock Cell Preparation System Kit. Briefly, the cassette was incubated in 70% 
ethanol, dewatered and embedded into liquid paraffin. One day later, the paraffin block was punched. 
The cell line TMA was created as described (Simon et al., 2004). Briefly, punched cylinders were 
brought into a recipient paraffin block with a semiautomatic robotic precision instrument. Four 
micrometer sections of the resulting TMA block were transferred to an adhesive coated slide system 
(Instrumedics, Hackensack, NJ). 
 
Statistics. Data from the TMA evaluation was collected in Excel (Microsoft Corporation, Redmond, 
WA) and transferred to JMP 5.1 software (SAS, Cary, NC). T-tests, analysis of variance tests, Chi-
Square tests and survival analysis (Kaplan-Meier) were all performed using the JMP software. 
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Results 
 
DNA copy number analysis using SNP arrays. Twenty-two of the thirty SNP Affymetrix arrays 
passed the rigorous quality control according to the criteria described in the Affymetrix and in the 
DChip manual. After thorough analysis of all of the samples (data not shown), two samples (sample 
26 and sample 27) showed a 9p24 amplification (Figure 1). Whereas the amplicon of sample 27 
spanned a region of about 3.5Mb comprising 13 genes, the clear-cut amplified region of sample 26 
was restricted to a small region of 0.7Mb involving only the NFIB gene. This could be observed using 
the DChip analysis method (Figure 1A) as well as using the DNAcopy visualization (Figure 1B). 
Successful verification of these two samples was done by applying a FISH probe against the NFIB 
gene (one example shown in Figure 1C). RNA expression analysis of these samples on the Affymetrix 
RNA arrays revealed high concordance between amplification on DNA level and RNA overexpression 
(Table 1). Differential expression of 9p24 amplified samples against 9p24 normal samples revealed 
several statistically significant differences (data not shown), but the NFIB gene was the only gene of 
that list localized in the above mentioned region (Table 1). Both, the DNA data as well as the RNA 
data concerning this region strongly suggest that the NFIB gene is the so-called candidate gene of the 
9p24 amplicon. 
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Figure 1. SNP array DNA copy number analysis. A) shows a heatmap representing the DNA copy 
numbers in colors (yellow: high DNA copy number). On the right, the amplified region is shown in 
detail with all the genes that are localized in that region. B) shows DNA copy number visualization 
along the whole chromosome 9. C) shows the verification of an amplified sample by FISH analysis. 
Green fluorescent points show NFIB gene copies. 
 
 
C9orf150 MPDZ NFIB CER1 SNAPC3 PSIP1
Normal samples - - 1.0 - - 1.0
Sample 26 - - +3.6 - - -1.7
Sample 27 - +3.3 +4.9 - +1.7 +4.7
DE: Normal vs 
Amplified
No No p < 0.0001 No No No
 
Table 1. Statistical analysis of the Affymetrix RNA expression arrays. Only genes are listed that are 
localized in the region shown in Figure 1. Present values are normalized to 1. Absent genes are 
marked with a hyphen. Only the NFIB transcript is statistically significantly elevated in amplified 
samples. DE: Differential expression between amplified and normal samples. 
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NFIB gene amplification analysis on 2200 breast cancers. In order to identify the role of NFIB gene 
amplification in a breast cancer population, our Breast Prognosis TMA containing 2200 breast tumors 
was subjected to NFIB gene FISH analysis. FISH analysis was successful in 1608 of 2197 (73.2%) 
arrayed breast cancer samples (Table 2). FISH analysis failed in 589 cases either due to lack of tumor 
cells in the spot or because of FISH-related problems, like weak hybridization and high background. 
Increased copy number of NFIB (at least twofold more NFIB gene copies than centromere 9 signals) 
was found in 5% of all breast cancers analyzed. Most of these amplified cases had moderate absolute 
copy numbers ranging between 4 and 10 NFIB gene copies. The associations with tumor phenotype 
are summarized in Table 2. Amplification rate of NFIB was not evenly distributed among the different 
histological subtypes in breast cancer. Medullary carcinomas showed a particularly high rate of NFIB 
amplification (19%, p = 0.0007). A similar rate was achieved by the apocrine tumors (22%, p = 
0.0908), but the low number of analyzable samples of this group (n = 9) diminished the significance of 
this result. NFIB gene amplification was strongly associated with tumor grade 3 (p < 0.0001), but no 
association was found with tumor or nodal stages. NFIB gene amplification was also significantly 
associated with tumor cell proliferation (p < 0.0001), as determined by the use of the Ki67 labeling 
index (LI) (Table 2B). This was also true by analyzing only grade 3 breast cancers (p = 0.0082). 
Higher proliferation rates were also found in the grade 1 and grade 2 subgroups, but due to the low 
numbers of amplified cases in those groups (n = 4 for grade 1, n = 13 for grade 2), no significant 
association was found. The impact of NFIB gene amplification on patient survival was also analyzed 
(Figure 2). Patients carrying a NFIB amplification showed a worse prognosis than normal NFIB 
patients (p = 0.0278), but this association seemed dependent of the grade, since the same analysis with 
only grade 3 patients did not show an effect (p = 0.4764). 
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A
on array (n) analyzable (n)
Increased copy 
number (n)
Increased copy 
number p
Breast Cancers all 2197 1608 76 5%
Histology ductal carcinoma 1552 1099 60 5%
lobular carcinoma 312 212 2 1% 0.0070*
mucinous carcinoma 69 45 0 0%
medullary carcinoma 58 48 9 19% 0.0007*
tubular carcinoma 56 33 0 0%
cribriform carcinoma 65 49 0 0%
papillary carcinoma 30 23 1 4%
apocrine carcinoma 15 9 2 22% 0.0908*
others 79 38 1 3%
pT stage pT1 820 541 22 4% 0.6521
pT2 1023 767 44 6%
pT3 124 100 3 3%
pT4 242 170 6 4%
Nodal stage pN0 950 689 30 4% 0.4239
pN1 793 578 33 6%
pN2 121 83 2 2%
BRE grade G1 545 378 4 1% <0.0001
G2 844 565 13 2%
G3 655 513 51 10%
*versus ductal carcinoma
NFIB amplification
 
B
NFIB and Ki67 LI
NFIB amplified 63 41.35 37.66 45.04
NFIB normal 1228 28.02 27.18 28.85
NFIB and Ki67 LI on Grade 3 tumors
NFIB amplified 41 45.02 40.44 49.61
NFIB normal 378 38.5 36.99 40.01
< 0.0001
p-value
0.0082
number mean Ki67 LI Lower 95% Upper 95%
Upper 95% p-valuenumber mean Ki67 LI Lower 95%
 
Table 2. Statistical analysis of the Breast Prognosis TMA comprising more than 2000 breast tumors. 
A) Statistical summaries. B) Influence of the NFIB amplification on the Ki67 proliferation index. 
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Figure 2. Survival analysis of the breast samples on the breast prognosis TMA. Breast tumors with 
elevated number of NFIB gene copies, show a worse survival prognosis during a 10-year-interval. 
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NFIB gene amplification analysis on 120 cell lines. In order to find cell lines carrying NFIB gene 
amplifications, our cell line TMA comprising more than 120 different human cell lines was subjected 
to FISH analysis with a probe against the NFIB gene. An overview of the cell lines of this TMA is 
listed as supplementary information. The human thyroid sarcoma cell line named S-117 was the only 
cell line found carrying such an amplification (i.e. more than two times more NFIB gene copies than 
chromosome 9 centromeres). None of the analyzed breast cell lines (SKBR3, T47D, MCF7, MDA-
MB-435, BT-549, BT-474, ZR-75-1) showed a NFIB gene amplification. 
 
NFIB gene knockdown leads to reduced proliferation levels. In order to further investigate the 
previously mentioned association between the NFIB gene amplification and the Ki67 LI, the effect of 
NFIB gene knockdown on cell proliferation was studied (Figure 3). First of all, two breast cell lines 
expressing the NFIB gene (T47D and MCF7, Figure 3A) and the cell line with the NFIB gene 
amplification (S-117, Figure 3A) were chosen for this analysis. After gene knockdown using siRNA, 
RNA expression levels dropped down to 20% (Figure 3B). The effect of this knockdown could also be 
observed three and four days later on protein levels (Figure 3C). The knockdown of NFIB on RNA 
and on protein level led to reduced cell proliferation (Figure 3D). The largest effect could be detected 
in the cell line MCF7, where a reduction of proliferation by 64% was achieved. 
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Figure 3. NFIB gene expression. A) shows NFIB RNA levels  of different tumor cell lines. Grey ones 
were chosen for further analysis. B) shows successful NFIB gene expression knockdown using 
siRNA. C) shows NFIB protein knockdown on whole cell lysates three and four days after 
transfection. D) shows attenuated cell growth of cells with reduced NFIB expression. 
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NFIB protein expression. Whole cell lysate western blot analysis with anti-NFIB revealed only one 
band at 60-65kDa (Figure 3C). In the database Swiss-Prot three isoforms for the human NFIB protein 
are described. A suggested "normal" isoform with a molecular weight (MW) of 47 kDa (Swiss-Prot: 
NFIB_HUMAN), a smaller one with a MW of 22 kDa, which was exclusively described in 1997 (Liu 
et al., 1997) and a third one without any further description or reference are listed. In order to analyze 
the different NFIB isoforms in our cell lines, we performed subcellular fractionation and western blot 
analysis with the only commercially available antibody (see materials and methods for description). 
The main isoform detected in all of the cell lines analyzed had a MW of around 60-65 kDa and was 
present in both, the cytosolic and in the nuclear fraction (Figure 4A-C). The 47 kDa isoform could 
only be detected by massive overloading of the gel with nuclear material (Figure 4C), suggesting that 
this isoform is only present in low amounts. Interestingly, the cell line S-117 showed an additional 
highly expressed protein isoform in the nuclear fraction at 55 kDa (Figure 4B and C). Using database 
searches (NCBI-Entrez, Expasy/TrEMBL and Enseml), two cDNA-isoforms for NFIB whose 
translational products have calculated MWs of 54.9kDa (TrEMBL: Q5VW27) or 55.2kDa (Q5VW29), 
were found. The exon structures of these two isoforms and of the "normal" isoform are shown in 
Figure 4D. Reverse-transcription PCR followed by nucleic acid sequencing proved the existence of 
Q5VW29 (55.2kDa) and excluded the presence of the Q5VW27 (54.9kDa) isoform (Figure 4E). 
The highly expressed protein isoform at 60-65kDa (Figure 4A) belongs either to the predicted protein 
product Q5VW30 (62.3kDa, TrEMBL) or to the isoform Q5VW26 (63.4kDa, TrEMBL). Using full 
length cDNA cloning, followed by nucleic acid sequencing, we were able to show that the Q5VW30 
isoform is present in all of the cell lines analyzed, but were not able to exclude the existence of the 
isoform Q5VW26 (data not shown). 
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Figure 4. NFIB protein expression pattern. A) shows NFIB protein expression in the cytosol. B) The 
amplified cell line S-117 shows a distinct nuclear NFIB expression pattern (red arrow). C) Only by 
overloading the gel with nuclear extracts, the normal isoform at 47kDa becomes detectable (green 
arrow). D) Overview of the exon structure of the isoforms mentioned above: NFIB_HUMAN as the 
"normal" isoform and Q5VW27 and Q5VW29 as the two isoforms whose translational products have 
a calculated MW of around 55 kDa. Primers are shown as red bars. The blue bar shows the position of 
the epitope of the antibody used. The green bar shows the DNA binding site of NFIB. E) Gel analysis 
of rt-PCR products generated using the primers from D. Pink arrow shows that only the S-117 
expresses the NFIB isoform whose translational product has a calculated MW of around 55 kDa. 
Nucleic acid sequencing of this band showed that this NFIB isoform is the Q5VW29 (55.2 kDa). 
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RNA expression analysis of NFIB expressing breast tumors. In order to find a role of the NFIB 
gene in breast cancer, we used a public Affymetrix RNA expression data set (GSE1456, GEO public 
repository) comprising expression arrays of 159 breast cancer patients. From this data set, we chose 
the 30 samples with the highest NFIB expression values and 33 samples with none or very low NFIB 
expression and subjected these two groups to differential expression analysis. Surprisingly, a huge 
number of differentially expressed genes (approximately 2500; 1600 with an absolute fold change of 
more than 1.4) after rigorous statistical analysis were detected. (The 500 most significant differentially 
expressed are listed in the supplemental section.) In order to visualize the distribution of the samples, 
an unsupervised correspondence analysis was performed. Colouring of the samples according to their 
NFIB expression status revealed the existence of two groups with only few crossing points (Figure 
5B). Additionally, a supervised Between Group Analysis (BGA) using the NFIB expression status as 
classifier was performed, leading to a similar result (Figure 5A). The so-called topgenes, i.e. the genes 
that best separated the two groups, were selected and compared to the 500 gene list mentioned above 
(supplemental data, Table S2 and S3). Almost all of the top ranked genes were present in both lists 
(92% overlapping in the top 100 genes). Several cancer-relevant genes were found to be positively 
(e.g. ID4, EGFR, PDGFRA, KIT) or negatively (e.g. ESR1) correlated with NFIB. 
Additional information provided with the public breast cancer data set used is the so-called genetic 
subtype first introduced by Perou and Sorlie (Perou et al., 2000; Sorlie et al., 2001). This information 
has been recently assigned to this data set (Calza et al., 2006). Application of this sample information 
to our two groups, revealed that 28 of the 33 samples (85%) with no or low NFIB expression had been 
characterized as luminal. But only 1 of 30 samples with a high NFIB gene expression belonged to that 
subtype (Figure 5C). 
This suggested a major role for NFIB in assisting the separation of the breast cancer samples into 
genetic subclasses. We analyzed the impact of the NFIB gene expression on the different subtypes 
using the full data set (159 breast cancer samples). The result was striking: NFIB gene expression was 
significantly different between the three groups (Figure 5D), showing highest expression levels in the 
basal-like and lowest levels in the luminal group. 
RESULTS: NFIB 
 
 86
C
A
B
High Low
No subtype 4 1
Luminal 1 28
Basal 13 2
Normal like 11 0
ERBB2 1 2
Subtype Samples
D
 High  Low 
NFIBNFIB NFIB
KRT14
SFRP1
NFIB
GABRP SFRP1
ID4
FABP4
ADH1B
PROM1
EGFR
ADH1B
ID4
ADIPOQ
KRT5
VTCN1
DMN
KRT17
KRT17
PLAGL1
ELF5
LPL
RARRES1
PTN
SRPX
KI
CSRP2
MMP7
CYP2B6
TFF1
GRIA2
TFF3
ESR1
NAT1
CA12
CA12
AGR2
AP1G1CA12 EEF1A2
CA12
SCUBE2
SERPINA3
CEACAM6
CPB1
CYP2B7P1
SERPINA1
GFRA1
SLC39A6
ABAT
TNRC9TNRC9
ACOX2
CRIP1
SPP1
DKFZp434L142
MCCC2
COL11A1
N
FI
B
0
500
1000
1500
2000
2500
Basal ERBB2 Luminal
Subtypes p-Value
Basal vs. Luminal < 0.0001
Basal vs. ERBB2 < 0.0001
 
Figure 5. NFIB gene expression analysis on the public breast cancer data set GSE1456. A) Between 
Group Analysis of the 63 selected samples using NFIB expression status as classifier leads to several 
genes which helps to separate the two groups. Programming code: courtesy of F. Baty. B) 
Unsupervised correspondence analysis of the 63 selected samples. Colouring according to the NFIB 
expression (red:  high NFIB expression, blue: low NFIB expression) revealed two groups. C) Genetic 
subtypes of the 63 samples selected. Only one luminal sample shows high NFIB gene expression. D) 
NFIB gene expression analysis on all of the 159 breast cancer samples revealed distinct expression 
levels of the different genetic subtypes. All Pairs Tukey HSD was used. 
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Discussion 
 
In this study, we have demonstrated the existence of NFIB gene amplifications in human breast 
cancer. This 9p24 amplification has never been described in breast cancer before. Similar to our 
recently published work about the ESR1 gene amplification, the NFIB gene amplification was first 
detected using Affymetrix SNP microarrays in only two cases, including one sample where the 
amplicon was limited to a size of less than 1 Mb, only comprising the NFIB gene. 
 
The use of a FISH probe for the NFIB gene allowed us to validate our findings on a large Breast 
Prognosis TMA comprising more than 2000 breast cancers. The overall NFIB gene amplification rate 
of 5% was similar to the MDM2 (5.7%) and CMYC (5%) amplification rates, previously defined 
using the same TMA. The correlation of the NFIB amplified samples with a higher proliferation index 
(Ki67 LI) suggested a potential role for NFIB as a proliferation supporting protein in breast cancer. 
This finding was confirmed by the results obtained by the RNA interference experiments. Knockdown 
of NFIB RNA, followed by NFIB protein reduction was accompanied by reduced levels of 
proliferation. The most impressive effect was obtained in the cell line MCF7, which showed a reduced 
proliferation of more than 60%. This may be explained by the observation that this cell line had the 
lowest NFIB expression levels under normal culture conditions. RNA knockdown in MCF7 cells may 
cause NFIB levels to fall below a threshold level required for continued proliferation. Since our RNA 
interference approach was designed to affect all of the described NFIB isoforms, it is not clear whether 
all of the isoforms influenced cell proliferation to the same extent. Western blot analysis revealed that 
the most prominent NFIB isoform in the cell lines tested, was by far not the so-called "normal" 
isoform with a MW of 47 kDa (SwissProt: NFIB_HUMAN), but an isoform with a MW around 63 
kDa. We were able to show the existence of the "predicted" NFIB isoform Q5VW30 with a calculated 
MW of 62.3 kDa, but further experiments are necessary to exclude the presence of other NFIB 
isoforms with similar MW. In addition, we were able to confirm that the NFIB protein product with a 
size of approximately 53 kDa in the cell line S-117 belongs to the "predicted" isoform Q5VW29. We 
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suggest an important role for this variant since it was found in the cell line with an amplified NFIB 
gene and the protein product could only be detected in the nuclear fraction of the cells, in contrast to 
the other main isoform which was prominent in the cytosol. 
 
The availability of a public Affymetrix expression data set comprising 159 breast cancers allowed us 
to study the influence of NFIB gene expression in breast cancer. The result was intriguing: data 
analysis of samples with highest, respectively lowest levels of NFIB revealed a clear cut separation of 
the breast tumors. Inclusion of additional public information describing the tumors analyzed revealed 
that NFIB was differentially expressed between the different molecular expression groups (luminal, 
basal and ERBB2) introduced by Perou and Sorlie (Perou et al., 2000; Sorlie et al., 2001). Breast 
cancer samples belonging to the basal group were characterized by the authors as ER and ERBB2 
negative, luminal samples as ER positive and samples belonging to the ERBB2 group as Her-2 
positive. Here we show that NFIB is highly expressed in the samples belonging to the basal group and 
lowest in the luminal breast cancers (p < 0.0001). An equivalent result was also obtained by 
investigating the top genes which best divided the NFIB high group from the NFIB low group (Figure 
5A and Supplemental tables S2 and S3). Several genes which had previously been defined to be 
characteristic for the basal-like group appeared as top ranked genes in the NFIB high group (e.g. 
KRT5 and KRT17). On the other hand, several genes which were said to be responsible for the 
characterization of the luminal group were top ranked in the NFIB low group, as for example the 
ESR1 gene. This finding was not surprising since we could show that most of the selected NFIB low 
samples (28 of 33, Figure 5C) were previously classified as luminal and were therefore ER positive. 
Similar observations were also obtained on DNA amplification levels on the Breast Prognosis TMA. 
NFIB gene amplification showed its highest rate on medullary carcinomas (19%, p = 0.0007). Since it 
has been shown that amplified genes tend to be overexpressed, these results are consistent with a 
recent publication which classified the medullary carcinomas as basal breast cancers (Bertucci et al., 
2006). These findings are further supported by the ESR1 FISH analysis on the same array, which 
showed by far its lowest rate on medullary carcinomas (2%, p < 0.0001) (manuscript under review, 
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Nature Genetics). This is again in accordance with previous data, since ER positive samples are 
classified as luminal and these show lowest NFIB expression levels. 
 
Since the NFIB gene is not only overexpressed in the basal group of breast cancers, but also amplified 
in a considerable fraction of them, we suggest that this gene is relevant for the development of these 
breast cancers. Our data from the NFIB gene knockdown indicate a role for NFIB to support tumor 
cell growth. 
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Supplemental Data 
Cell lines on the cell line tissue microarray 
Cell line name ATCC-Nr. Organ Cell line name ATCC-Nr. Organ
SKBR-3 HTB-30 breast A 549 CCL-185 lung
T47D HTB-133 breast NCI-H460 HTB-177 lung
MCF 7 HTB-22 breast NCI-H226 CRL-5826 lung
MDA-MB-435 HTB-129 breast NCI-H522 CRL-5810 lung
BT-549 HTB-122 breast HOP-62 lung
BT-474 HTB 20 breast EKVX lung
MBA-MD-415 breast NCI-H322M lung
HBL100 HTB-124 breast NCI-H23 CRL-5800 lung
ZR-75-1 CRL-1500 breast MRC-5 CCL-171 lung
MBA-MB-453 breast NCI-H82 HTB-175 lung
BT-474 HTB-20 breast NCI-H51OA lung
SK-OV-3 HTB-77 ovary MALME-3M lung metastasis
OVCAR-3 ovary 8505C 219 thyroid carcinoma
OVCAR-8 ovary CAL_62 thyroid carcinoma
OVCAR-4 ovary BHT-101 thyroid carcinoma
OVAR-5 ovary ONCO-DG-1 thyroid carcinoma
HELA CCL-2 cervix B-C PAP thyroid carcinoma
786-O CRL-1932 kidney ML-1 thyroid carcinoma
CAK I kidney 8305 c thyroid carcinoma
A 498 HTB-44 kidney S-117 thyroid gland
ACHN CRL-1611 kidney SK-MEL-2 HTB-68 skin  
786-O CRL-1932 kidney SK-MEL-5 HTB-70 skin  
Caki-2 kidney A 375 CRL-1619 skin  
293 CRL-1573 kidney A 431 CRL-2592 skin  
COS 1 CRL-1650 kidney UACC 257 malignant melanoma
WS-1 CRL-2029 kidney UACC-62 malignant melanoma
TK10 renal MEL-HO melanoma
UO-31 renal SM melanoma
J82 HTB-1 urinary M14 amelanotic melanoma
SCaBER HTB-3 urinary T98G CRL-1690 brain
T24 HTB-4 urinary U-138 MG HTB-16 brain
HT-1376 CRL-1472 urinary A172 CRL-1620 brain
5637 HTB-9 urinary U87-MB HTB-14 brain
TCCSUP HTB-5 urinary SNB-19 cns
RT-112 urinary SF 268 cns
KU-19-19 urinary SF-539 cns
CRL 7930 urinary SF-295 cns
DLD-1 CCL-221 colon U 251 cns/ glioma
COLO 320 DM CCL-220 colon LN 229 glioblastoma
COLO 201 CCL-224 colon LN 401 glioblastoma
RKO CRL-2577 colon DBTRG glioblastoma
SW-480 CCL-228 colon GAMG p6 glioma
HAT-29 HTB-38 colon LN 405 p 9 astrocytom
SK-CO-1 HTB-39 colon SJCRH-30WCB neuroblastom
SW-403 CCl-230 colon OCI-LY19 bone
HCT 116 CCL-247 colon MOLT-4 CRL-1582 peripheral blood
HCT 15 CCL-225 colon IM-9 CCL-159 peripheral blood
SW-620 CCL-227 colon CRO-AP 3 b-cell-lymphoma
HT29 HTB-38 colon IGR1 groin lymphnode
COLO 205 CCL-222 colon SR CRL-2262 immunoblastic large cell lymphoma
HCL-2998 colon COLO 849 right axillary lymphnode
CCL-244 colon HUVEC endothelial
HCT 8 CCL-244 colon HUT 12 fibrosarcoma
SW-948 CCL-237 colon HT CRL-2260 ascites
Hep-G2 HB-8065 liver SU-DHL-4 peritoneal effussion
HS-766 T pancreatic SU-DHL-6 peritoneal effussion
PC-3 prostata  
Supplemental table S1. Listing of the cell lines present on the cell line tissue microarray. 
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Differential expressed genes based on the NFIB expression status. 
Upregulated genes: 
Affy_ProbeID GeneSymbol Description Fold Change p-Value
209351_at KRT14 keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) 15.3 0.000030
205044_at GABRP gamma-aminobutyric acid (GABA) A receptor, pi 15.0 0.000000
209289_at NFIB nuclear factor I/B 11.1 0.000000
209613_s_at ADH1B alcohol dehydrogenase IB (class I), beta polypeptide 10.7 0.000019
209292_at ID4 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 9.5 0.000001
202037_s_at SFRP1 secreted frizzled-related protein 1 8.0 0.000000
207175_at ADIPOQ adiponectin, C1Q and collagen domain containing 7.9 0.001936
203980_at FABP4 fatty acid binding protein 4, adipocyte 7.9 0.000282
220625_s_at ELF5 E74-like factor 5 (ets domain transcription factor) 7.5 0.005698
205157_s_at KRT17 keratin 17 7.4 0.000258
203548_s_at LPL lipoprotein lipase 7.3 0.001069
201820_at KRT5 keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber 6.5 0.000012
204455_at DST dystonin 5.7 0.009781
211737_x_at PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting f 5.7 0.015979
204304_s_at PROM1 prominin 1 5.6 0.000109
212730_at DMN desmuslin 5.3 0.000000
209894_at LEPR leptin receptor 4.9 0.000169
201983_s_at EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) 4.7 0.000000
203400_s_at TF transferrin 4.2 0.006400
204259_at MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 4.0 0.002927
211726_s_at FMO2 flavin containing monooxygenase 2 3.9 0.000008
209763_at CHRDL1 chordin-like 1 3.9 0.000000
213524_s_at G0S2 G0/G1switch 2 3.8 0.035328
209283_at CRYAB crystallin, alpha B 3.8 0.000001
204855_at SERPINB5 serpin peptidase inhibitor, clade B (ovalbumin), member 5 3.7 0.014040
221872_at RARRES1 retinoic acid receptor responder (tazarotene induced) 1 3.5 0.000020
209318_x_at PLAGL1 pleiomorphic adenoma gene-like 1 3.5 0.000000
204719_at ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 3.5 0.000451
208335_s_at DARC Duffy blood group, chemokine receptor 3.4 0.000226
204151_x_at AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1 3.4 0.018950
202746_at ITM2A integral membrane protein 2A 3.4 0.003419
205051_s_at KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 3.4 0.000046
209540_at IGF1 insulin-like growth factor 1 (somatomedin C) 3.3 0.010939
202274_at ACTG2 actin, gamma 2, smooth muscle, enteric 3.3 0.044845
209392_at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) 3.3 0.000736
207030_s_at CSRP2 cysteine and glycine-rich protein 2 3.2 0.000000
219497_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 3.1 0.001525
204955_at SRPX sushi-repeat-containing protein, X-linked 3.1 0.000027
209047_at AQP1 aquaporin 1 (Colton blood group) 3.1 0.000000
201540_at FHL1 four and a half LIM domains 1 3.0 0.019119
203131_at PDGFRA platelet-derived growth factor receptor, alpha polypeptide 3.0 0.001425
203706_s_at FZD7 frizzled homolog 7 (Drosophila) 2.9 0.000000
201348_at GPX3 glutathione peroxidase 3 (plasma) 2.9 0.034153
202555_s_at MYLK myosin, light polypeptide kinase 2.9 0.002204
212771_at C10orf38 chromosome 10 open reading frame 38 2.9 0.000000
209774_x_at CXCL2 chemokine (C-X-C motif) ligand 2 2.9 0.032566
202342_s_at TRIM2 tripartite motif-containing 2 2.9 0.000008
202760_s_at PALM2-AKAP2 2.8 0.003870
214456_x_at SAA2 serum amyloid A2 2.8 0.000150
219768_at VTCN1 V-set domain containing T cell activation inhibitor 1 2.8 0.000012
209205_s_at LMO4 LIM domain only 4 2.7 0.000003
201497_x_at MYH11 myosin, heavy polypeptide 11, smooth muscle 2.7 0.000004
207808_s_at PROS1 protein S (alpha) 2.7 0.000006
207057_at SLC16A7 solute carrier family 16 (monocarboxylic acid transporters), member 7 2.6 0.033920
201579_at FAT FAT tumor suppressor homolog 1 (Drosophila) 2.6 0.000000
207480_s_at MEIS2 Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse) 2.6 0.002431
823_at CX3CL1 chemokine (C-X3-C motif) ligand 1 2.6 0.027118
213564_x_at HSPA8 heat shock 70kDa protein 8 2.6 0.000000
202965_s_at CAPN6 calpain 6 2.6 0.046439
202350_s_at MATN2 matrilin 2 2.6 0.000029
213451_x_at TNXB tenascin XB 2.6 0.001687
219563_at C14orf139 chromosome 14 open reading frame 139 2.5 0.000512
203637_s_at MID1 midline 1 (Opitz/BBB syndrome) 2.4 0.000000
218736_s_at PALMD palmdelphin 2.4 0.000220
201030_x_at LDHB lactate dehydrogenase B 2.4 0.000000
214051_at MGC39900 2.4 0.019306
205392_s_at CCL14 chemokine (C-C motif) ligand 14 2.4 0.006287
204750_s_at DSC2 desmocollin 2 2.4 0.006075
202973_x_at FAM13A1 family with sequence similarity 13, member A1 2.4 0.000625
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Affy_ProbeID GeneSymbol Description Fold Change p-Value
206560_s_at MIA melanoma inhibitory activity 2.4 0.042449
204359_at FLRT2 fibronectin leucine rich transmembrane protein 2 2.4 0.002051
203323_at CAV2 caveolin 2 2.4 0.000208
203951_at CNN1 calponin 1, basic, smooth muscle 2.3 0.011330
203632_s_at GPRC5B G protein-coupled receptor, family C, group 5, member B 2.3 0.000000
209170_s_at GPM6B glycoprotein M6B 2.3 0.014103
221748_s_at TNS1 tensin 1 2.2 0.000635
213348_at CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 2.2 0.000116
203256_at CDH3 cadherin 3, type 1, P-cadherin (placental) 2.2 0.036454
203510_at MET met proto-oncogene (hepatocyte growth factor receptor) 2.2 0.000011
203574_at NFIL3 nuclear factor, interleukin 3 regulated 2.2 0.000007
208798_x_at GOLGA8A golgi autoantigen, golgin subfamily a, 8A 2.2 0.017342
206953_s_at LPHN2 latrophilin 2 2.2 0.000003
203373_at SOCS2 suppressor of cytokine signaling 2 2.2 0.044004
212762_s_at TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 2.2 0.000001
209183_s_at C10orf10 chromosome 10 open reading frame 10 2.2 0.000035
213260_at FOXC1 forkhead box C1 2.2 0.000081
209355_s_at PPAP2B phosphatidic acid phosphatase type 2B 2.2 0.028322
210024_s_at UBE2E3 ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog, yeast) 2.2 0.000000
204897_at PTGER4 prostaglandin E receptor 4 (subtype EP4) 2.2 0.009698
202992_at C7 complement component 7 2.1 0.009689
201300_s_at PRNP prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler- 2.1 0.000012
208370_s_at DSCR1 Down syndrome critical region gene 1 2.1 0.000795
209074_s_at FAM107A family with sequence similarity 107, member A 2.1 0.010565
202133_at WWTR1 WW domain containing transcription regulator 1 2.1 0.000015
208131_s_at PTGIS prostaglandin I2 (prostacyclin) synthase 2.1 0.000016
218236_s_at PRKD3 protein kinase D3 2.1 0.000015
203180_at ALDH1A3 aldehyde dehydrogenase 1 family, member A3 2.1 0.035185
204326_x_at MT1L metallothionein 1L 2.0 0.004895
203408_s_at SATB1 special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaf 2.0 0.002413
212558_at SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 2.0 0.003633
209369_at ANXA3 annexin A3 2.0 0.003498
212724_at RND3 Rho family GTPase 3 2.0 0.003076
219134_at ELTD1 EGF, latrophilin and seven transmembrane domain containing 1 2.0 0.035824
209108_at TSPAN6 tetraspanin 6 2.0 0.002146
213844_at HOXA5 homeobox A5 2.0 0.000018
201160_s_at CSDA cold shock domain protein A 2.0 0.000109
210473_s_at CDC2L2 cell division cycle 2-like 2 (PITSLRE proteins) 2.0 0.000658
218319_at PELI1 pellino homolog 1 (Drosophila) 2.0 0.000000
206453_s_at NDRG2 NDRG family member 2 2.0 0.001007
204400_at EFS embryonal Fyn-associated substrate 2.0 0.012968
217833_at SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein 1.9 0.000000
219093_at FLJ20701 1.9 0.040636
209212_s_at KLF5 Kruppel-like factor 5 (intestinal) 1.9 0.040609
221016_s_at TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) 1.9 0.000000
204159_at CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 1.9 0.000024
204042_at WASF3 WAS protein family, member 3 1.9 0.000024
210946_at PPAP2A phosphatidic acid phosphatase type 2A 1.9 0.000674
219064_at ITIH5 inter-alpha (globulin) inhibitor H5 1.9 0.019792
204011_at SPRY2 sprouty homolog 2 (Drosophila) 1.9 0.011280
218031_s_at 1.8 0.013477
201034_at ADD3 adducin 3 (gamma) 1.8 0.040335
212263_at QKI quaking homolog, KH domain RNA binding (mouse) 1.8 0.000019
218486_at KLF11 Kruppel-like factor 11 1.8 0.000000
202146_at IFRD1 interferon-related developmental regulator 1 1.8 0.003469
203038_at PTPRK protein tyrosine phosphatase, receptor type, K 1.8 0.001707
201328_at ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 1.8 0.000043
204872_at TLE4 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 1.8 0.000003
218019_s_at 1.8 0.000000
203088_at FBLN5 fibulin 5 1.8 0.018248
202933_s_at YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 1.8 0.008264
204223_at PRELP proline/arginine-rich end leucine-rich repeat protein 1.8 0.001106
200762_at DPYSL2 dihydropyrimidinase-like 2 1.8 0.018297
209373_at MALL mal, T-cell differentiation protein-like 1.8 0.042302
212589_at RRAS2 related RAS viral (r-ras) oncogene homolog 2 1.8 0.033426
209897_s_at SLIT2 slit homolog 2 (Drosophila) 1.7 0.022056
212345_s_at CREB3L2 cAMP responsive element binding protein 3-like 2 1.7 0.000493
215039_at LOC339524 1.7 0.010515
201811_x_at SH3BP5 SH3-domain binding protein 5 (BTK-associated) 1.7 0.001735
203895_at PLCB4 phospholipase C, beta 4 1.7 0.002575
212614_at ARID5B AT rich interactive domain 5B (MRF1-like) 1.7 0.001779
213541_s_at ERG v-ets erythroblastosis virus E26 oncogene like (avian) 1.7 0.000039
221556_at CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) 1.7 0.000423  
Supplemental table S2. Genes that are upregulated on the NFIB high expressing samples. Genes 
marked in grey were also present on the topgenes of the Between Group Analysis. P-values have been 
adjusted according to Benjamini and Hochberg. Duplicate gene entries were removed. 
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Downregulated genes: 
Affy_ProbeID GeneSymbol Description Fold Change p-Value
205358_at GRIA2 glutamate receptor, ionotropic, AMPA 2 -14.6 0.019359
206754_s_at CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6 -7.1 0.000001
204623_at TFF3 trefoil factor 3 (intestinal) -5.0 0.000028
205364_at ACOX2 acyl-Coenzyme A oxidase 2, branched chain -4.7 0.000026
205009_at TFF1 trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed i -4.7 0.026084
221577_x_at GDF15 growth differentiation factor 15 -4.3 0.017850
210272_at CYP2B7P1 cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1 -4.1 0.000002
219872_at C4orf18 chromosome 4 open reading frame 18 -3.8 0.000197
201884_at CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 -3.7 0.009543
204540_at EEF1A2 eukaryotic translation elongation factor 1 alpha 2 -3.7 0.000282
205696_s_at GFRA1 GDNF family receptor alpha 1 -3.6 0.000127
209460_at ABAT 4-aminobutyrate aminotransferase -3.5 0.009234
204597_x_at STC1 stanniocalcin 1 -3.3 0.003454
210735_s_at CA12 carbonic anhydrase XII -3.3 0.000000
216623_x_at TNRC9 trinucleotide repeat containing 9 -3.2 0.017680
218280_x_at HIST2H2AA histone 2, H2aa -3.1 0.000516
209624_s_at MCCC2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) -3.0 0.000000
202376_at SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), -2.8 0.003104
215867_x_at AP1G1 adaptor-related protein complex 1, gamma 1 subunit -2.7 0.000740
204070_at RARRES3 retinoic acid receptor responder (tazarotene induced) 3 -2.7 0.031627
202089_s_at SLC39A6 solute carrier family 39 (zinc transporter), member 6 -2.7 0.017770
203876_s_at MMP11 matrix metallopeptidase 11 (stromelysin 3) -2.6 0.001742
201130_s_at CDH1 cadherin 1, type 1, E-cadherin (epithelial) -2.5 0.012849
218532_s_at FLJ20152 -2.4 0.003561
201841_s_at HSPB1 heat shock 27kDa protein 1 -2.4 0.000305
203771_s_at BLVRA biliverdin reductase A -2.4 0.000003
205645_at REPS2 RALBP1 associated Eps domain containing 2 -2.3 0.012407
203108_at GPRC5A G protein-coupled receptor, family C, group 5, member A -2.3 0.004445
215552_s_at ESR1 estrogen receptor 1 -2.3 0.000001
205081_at CRIP1 cysteine-rich protein 1 (intestinal) -2.2 0.005826
208682_s_at MAGED2 melanoma antigen family D, 2 -2.2 0.000064
201169_s_at BHLHB2 basic helix-loop-helix domain containing, class B, 2 -2.2 0.000250
218510_x_at FLJ20152 -2.2 0.000027
219438_at FAM77C family with sequence similarity 77, member C -2.2 0.003006
217202_s_at GLUL glutamate-ammonia ligase (glutamine synthetase) -2.1 0.007699
202489_s_at FXYD3 FXYD domain containing ion transport regulator 3 -2.1 0.037247
219051_x_at METRN meteorin, glial cell differentiation regulator -2.1 0.000001
209276_s_at GLRX glutaredoxin (thioltransferase) -2.1 0.000002
201107_s_at THBS1 thrombospondin 1 -2.1 0.000005
201596_x_at KRT18 keratin 18 -2.1 0.033621
201754_at COX6C cytochrome c oxidase subunit VIc -2.1 0.000030
201563_at SORD sorbitol dehydrogenase -2.0 0.031669
201461_s_at MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 -2.0 0.001783
218409_s_at DNAJC1 DnaJ (Hsp40) homolog, subfamily C, member 1 -2.0 0.000029
200923_at LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein -2.0 0.011551
204934_s_at HPN hepsin (transmembrane protease, serine 1) -1.9 0.000001
202121_s_at CHMP2A chromatin modifying protein 2A -1.9 0.000006
202308_at SREBF1 sterol regulatory element binding transcription factor 1 -1.9 0.012844
202996_at POLD4 polymerase (DNA-directed), delta 4 -1.9 0.000000
204006_s_at FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b) -1.9 0.021015
210085_s_at ANXA9 annexin A9 -1.9 0.000296
202545_at PRKCD protein kinase C, delta -1.9 0.000000
208677_s_at BSG basigin (Ok blood group) -1.9 0.027673
207549_x_at CD46 CD46 antigen, complement regulatory protein -1.9 0.010264
213419_at APBB2 amyloid beta (A4) precursor protein-binding, family B, member 2 (Fe65- -1.9 0.000001
200862_at DHCR24 24-dehydrocholesterol reductase -1.8 0.043355
222067_x_at HIST1H2BD histone 1, H2bd -1.8 0.005305
214269_at MFSD7 major facilitator superfamily domain containing 7 -1.8 0.013211
209417_s_at IFI35 interferon-induced protein 35 -1.8 0.046785
204981_at SLC22A18 solute carrier family 22 (organic cation transporter), member 18 -1.8 0.000002
208621_s_at VIL2 villin 2 (ezrin) -1.8 0.000533
201349_at SLC9A3R1 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulat -1.8 0.021231
217234_s_at VIL2 villin 2 (ezrin) -1.8 0.013253
208934_s_at LGALS8 lectin, galactoside-binding, soluble, 8 (galectin 8) -1.8 0.000101
220240_s_at TMCO3 transmembrane and coiled-coil domains 3 -1.8 0.008691
205354_at GAMT guanidinoacetate N-methyltransferase -1.7 0.000008
218813_s_at SH3GLB2 SH3-domain GRB2-like endophilin B2 -1.7 0.001294
203071_at SEMA3B sema domain, immunoglobulin domain (Ig), short basic domain, secrete -1.7 0.033097
220744_s_at IFT122 intraflagellar transport 122 homolog (Chlamydomonas) -1.7 0.017281
202201_at BLVRB biliverdin reductase B (flavin reductase (NADPH)) -1.7 0.001106
207782_s_at PSEN1 presenilin 1 (Alzheimer disease 3) -1.7 0.000437
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Affy_ProbeID GeneSymbol Description Fold Change p-Value
206472_s_at TLE3 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) -1.7 0.000000
211015_s_at HSPA4 heat shock 70kDa protein 4 -1.7 0.000012
220540_at KCNK15 potassium channel, subfamily K, member 15 -1.7 0.035033
212637_s_at WWP1 WW domain containing E3 ubiquitin protein ligase 1 -1.7 0.026216
221759_at G6PC3 glucose 6 phosphatase, catalytic, 3 -1.7 0.000025
210246_s_at ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 -1.7 0.000000
203228_at PAFAH1B3 platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 -1.7 0.000017
203252_at CDK2AP2 CDK2-associated protein 2 -1.7 0.005450
203143_s_at LOC147299 -1.7 0.017562
220588_at BCAS4 breast carcinoma amplified sequence 4 -1.7 0.000001
201284_s_at APEH N-acylaminoacyl-peptide hydrolase -1.7 0.000003
212446_s_at LASS6 LAG1 longevity assurance homolog 6 (S. cerevisiae) -1.6 0.008539
214196_s_at TPP1 tripeptidyl peptidase I -1.6 0.029728
210904_s_at IL13RA1 interleukin 13 receptor, alpha 1 -1.6 0.000273
214446_at ELL2 elongation factor, RNA polymerase II, 2 -1.6 0.001428
203880_at COX17 COX17 homolog, cytochrome c oxidase assembly protein (yeast) -1.6 0.002081
218394_at ROGDI rogdi homolog (Drosophila) -1.6 0.001589
208583_x_at HIST1H2AJ histone 1, H2aj -1.6 0.000001
209367_at STXBP2 syntaxin binding protein 2 -1.6 0.000000
219709_x_at C16orf24 chromosome 16 open reading frame 24 -1.6 0.000480
209149_s_at TM9SF1 transmembrane 9 superfamily member 1 -1.6 0.000001
216202_s_at SPTLC2 serine palmitoyltransferase, long chain base subunit 2 -1.6 0.000027
200846_s_at PPP1CA protein phosphatase 1, catalytic subunit, alpha isoform -1.6 0.000730
216988_s_at PTP4A2 protein tyrosine phosphatase type IVA, member 2 -1.6 0.004742
200776_s_at LOC151579 -1.6 0.001281
202641_at ARL3 ADP-ribosylation factor-like 3 -1.6 0.001660
214522_x_at HIST1H2AD histone 1, H2ad -1.6 0.000460
218556_at ORMDL2 ORM1-like 2 (S. cerevisiae) -1.6 0.000008
202740_at ACY1 aminoacylase 1 -1.6 0.002389
210534_s_at EPPB9 -1.6 0.008091
207809_s_at ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 1 -1.6 0.000935
218436_at SIL1 SIL1 homolog, endoplasmic reticulum chaperone (S. cerevisiae) -1.6 0.004556
215891_s_at GM2A GM2 ganglioside activator -1.6 0.026880
210720_s_at APBA2BP amyloid beta (A4) precursor protein-binding, family A, member 2 binding -1.6 0.000077
220613_s_at SYTL2 synaptotagmin-like 2 -1.6 0.000017
202528_at GALE UDP-galactose-4-epimerase -1.6 0.017502
218921_at SIGIRR single immunoglobulin and toll-interleukin 1 receptor (TIR) domain -1.6 0.000282
204862_s_at NME3 non-metastatic cells 3, protein expressed in -1.6 0.004424
221823_at LOC90355 -1.6 0.003597
201096_s_at ARF4 ADP-ribosylation factor 4 -1.6 0.000005
200803_s_at TEGT testis enhanced gene transcript (BAX inhibitor 1) -1.6 0.001915
219562_at RAB26 RAB26, member RAS oncogene family -1.6 0.000016
202587_s_at AK1 adenylate kinase 1 -1.6 0.000541
201457_x_at BUB3 BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) -1.5 0.000045
200078_s_at ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b -1.5 0.002715
221882_s_at TMEM8 transmembrane protein 8 (five membrane-spanning domains) -1.5 0.013758
203458_at SPR sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) -1.5 0.000044
218866_s_at POLR3K polymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDa -1.5 0.002110
201583_s_at SEC23B Sec23 homolog B (S. cerevisiae) -1.5 0.031603
212495_at JMJD2B jumonji domain containing 2B -1.5 0.019902
212400_at FAM102A family with sequence similarity 102, member A -1.5 0.000001
218189_s_at NANS N-acetylneuraminic acid synthase (sialic acid synthase) -1.5 0.026942
211495_x_at TNFSF13 tumor necrosis factor (ligand) superfamily, member 13 -1.5 0.000018
202180_s_at MVP major vault protein -1.5 0.001008
208872_s_at REEP5 receptor accessory protein 5 -1.5 0.002465
220937_s_at ST6GALNAC4 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalact -1.5 0.033984
209177_at C3orf60 chromosome 3 open reading frame 60 -1.5 0.000351
205455_at MST1R macrophage stimulating 1 receptor (c-met-related tyrosine kinase) -1.5 0.000841
217770_at PIGT phosphatidylinositol glycan, class T -1.5 0.000021
212574_x_at C19orf6 chromosome 19 open reading frame 6 -1.5 0.020814
218302_at PSENEN presenilin enhancer 2 homolog (C. elegans) -1.5 0.025941
200769_s_at MAT2A methionine adenosyltransferase II, alpha -1.5 0.003115
208270_s_at RNPEP arginyl aminopeptidase (aminopeptidase B) -1.5 0.000647
210974_s_at AP3D1 adaptor-related protein complex 3, delta 1 subunit -1.5 0.000073
209872_s_at PKP3 plakophilin 3 -1.5 0.016472
221754_s_at CORO1B coronin, actin binding protein, 1B -1.5 0.007073
206491_s_at NAPA N-ethylmaleimide-sensitive factor attachment protein, alpha -1.5 0.003131
203258_at DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) -1.5 0.032251
218291_at MAPBPIP -1.5 0.000058
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220477_s_at C20orf30 chromosome 20 open reading frame 30 -1.5 0.023263
209665_at CYB561D2 cytochrome b-561 domain containing 2 -1.5 0.000005
214992_s_at DNASE2 deoxyribonuclease II, lysosomal -1.5 0.008132
211113_s_at ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 -1.5 0.010944
218548_x_at TEX264 testis expressed sequence 264 -1.5 0.006374
200085_s_at TCEB2 transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B) -1.5 0.000026
216483_s_at C19orf10 chromosome 19 open reading frame 10 -1.5 0.000020
217927_at SPCS1 signal peptidase complex subunit 1 homolog (S. cerevisiae) -1.5 0.000002
218262_at FLJ22318 -1.5 0.000192
218010_x_at C20orf149 chromosome 20 open reading frame 149 -1.5 0.014961
204088_at P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 -1.5 0.015753
200096_s_at ATP6V0E ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e -1.5 0.034068
201471_s_at SQSTM1 sequestosome 1 -1.4 0.001966
218688_at DAK dihydroxyacetone kinase 2 homolog (yeast) -1.4 0.002899
201003_x_at Kua-UEV -1.4 0.000259
209731_at NTHL1 nth endonuclease III-like 1 (E. coli) -1.4 0.002775
218931_at RAB17 RAB17, member RAS oncogene family -1.4 0.002628
221946_at C9orf116 chromosome 9 open reading frame 116 -1.4 0.000001
204398_s_at EML2 echinoderm microtubule associated protein like 2 -1.4 0.000082
200929_at TMED10 transmembrane emp24-like trafficking protein 10 (yeast) -1.4 0.000077
203054_s_at TCTA T-cell leukemia translocation altered gene -1.4 0.001556
221585_at CACNG4 calcium channel, voltage-dependent, gamma subunit 4 -1.4 0.003035
214687_x_at ALDOA aldolase A, fructose-bisphosphate -1.4 0.009821
203890_s_at DAPK3 death-associated protein kinase 3 -1.4 0.001814
200622_x_at CALM3 calmodulin 3 (phosphorylase kinase, delta) -1.4 0.000811
217785_s_at YKT6 -1.4 0.013313
204125_at NDUFAF1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly fact -1.4 0.024381
208911_s_at PDHB pyruvate dehydrogenase (lipoamide) beta -1.4 0.000004
203246_s_at TUSC4 tumor suppressor candidate 4 -1.4 0.000554
211622_s_at ARF3 ADP-ribosylation factor 3 -1.4 0.000302
217748_at ADIPOR1 adiponectin receptor 1 -1.4 0.000865
203272_s_at TUSC2 tumor suppressor candidate 2 -1.4 0.000210
202852_s_at FLJ11506 -1.4 0.032850
209853_s_at PSME3 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma,  K -1.4 0.000138
212995_x_at FLJ14346 -1.4 0.034196
208689_s_at RPN2 ribophorin II -1.4 0.003273
219203_at C14orf122 chromosome 14 open reading frame 122 -1.4 0.000004
217977_at SEPX1 selenoprotein X, 1 -1.4 0.000299
219725_at TREM2 triggering receptor expressed on myeloid cells 2 -1.4 0.000289
204824_at ENDOG endonuclease G -1.4 0.017578
202296_s_at RER1 RER1 retention in endoplasmic reticulum 1 homolog (S. cerevisiae) -1.4 0.021011
57540_at RBKS ribokinase -1.4 0.016288
202143_s_at COPS8 COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis) -1.4 0.016403
200736_s_at GPX1 glutathione peroxidase 1 -1.4 0.012940
218567_x_at DPP3 dipeptidyl-peptidase 3 -1.4 0.016852
221856_s_at FAM63A family with sequence similarity 63, member A -1.4 0.000575
36994_at ATP6V0C ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c -1.4 0.034177
218112_at MRPS34 mitochondrial ribosomal protein S34 -1.4 0.000110
221512_at C1orf160 chromosome 1 open reading frame 160 -1.4 0.022190
204262_s_at PSEN2 presenilin 2 (Alzheimer disease 4) -1.4 0.011113
212729_at DLG3 discs, large homolog 3 (neuroendocrine-dlg, Drosophila) -1.4 0.000439
213057_at ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2 -1.4 0.000443
 
Supplemental Table S3. Genes that are downregulated on the NFIB high expressing samples. Genes 
marked in grey were also present on the topgenes of the Between Group Analysis. P-values have been 
adjusted according to Benjamini and Hochberg. Duplicate gene entries were removed. 
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3. Discussion 
Breast cancer is the most common form of cancer and the most common cause of cancer death in 
females, worldwide (Sasco et al., 2003). It will affect approximately one out of twelve women at some 
stage in their life. Although the incidence as well as the prevalence of this disease in western countries 
increases, the mortality is decreasing due to improved treatment of breast cancer patients. 
Nevertheless, the decision making for treatment is delicate, since breast tumors are heterogeneous and 
consist of several pathological subtypes with different clinical presentations and outcomes. In addition, 
patients show a diverse range of responses to a given treatment. The decision making on adjuvant 
therapy is more and more influenced or even determined by molecular biological findings. Estrogen 
receptor and progesterone receptor positive patients are treated with anti-hormonal therapy. 
Diagnostics can even go further to the genomic level, as in the case of HER-2 gene amplification 
detection. Patients with a positive finding will be administered Herceptin. In the last decades the role 
of amplifications in cancer has become indisputable. Besides HER-2, several other oncogenes could 
be localized on amplified regions, for example CCND1 at 11q13 (Karlseder et al., 1994) or MDM2 at 
12q13 (Courjal et al., 1996). 
 
In our study we were able to identify several novel amplified regions in breast cancer. Two of them 
were further investigated: the 6q25 and the 9p24 gene amplifications. 
The 6q25 amplification comprising the ESR1 gene was the most astonishing finding in our study. It is 
remarkable, that the importance of the ESR1 gene amplification, which is of one the most or maybe 
even the most frequent amplification in breast cancer (21%), has not been discovered earlier. This is 
particularly surprising since ER expression levels are routinely measured for diagnosis and represent a 
major factor for treatment decision. The difficulties detecting this amplification are likely due to the 
small size of the amplicon; in one case the amplicon only measured 514 Kb. Although ESR1 
amplification frequency is relatively high, it is only present in a subset of about 50% of the breast 
cancers expressing high ER levels (on IHC). Further statistical analysis of these results in combination 
with additional data about the treatment these patients had received, revealed ESR1 gene amplified 
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patients as a subgroup of ER (IHC) positive patients with a much higher likelihood to positively 
respond to anti-hormonal therapy. We could also show that ESR1 gene amplification can be present in 
premalignant breast lesions which may have an increased potential for malignant transformation. All 
these findings advocate a major impact of ESR1 gene amplification on decision making regarding 
anti-hormonal therapy in breast cancer patients. Our findings are supported by the data available from 
public resources. As mentioned before (Introduction), Sorlie et al showed that the luminal genetic 
subgroups were associated with best survival in comparison to ER negative groups (i.e. basal-like and 
HER-2 group) (Figure 12). They reproduced these findings on another breast cancer data set and 
showed that the luminal A group, which is the ER high-expressing group, has a markedly better 
survival than the luminal B group (low to moderate ER expression levels) (Figure 12). The authors 
denote this finding as an intriguing result, since both luminal groups are ER positive. Further, they 
suggest that the luminal B subtype may reflect a group of patients who will not benefit from adjuvant 
Tamoxifen. This suggestion completely reflects our findings on the effect of ESR1 gene amplification 
on Tamoxifen drug response. This may lead to the solution of the long-lasting mystery of the two 
luminal subgroups, suggesting that the luminal A group is the ER positive ESR1 amplified group, and 
the luminal B group is not ESR1 amplified, but still ER positive. Successful demonstration of these 
findings would make it reasonable to analyze genes differentially expressed between these two 
luminal groups. This would help us to find genes which are responsible for the different behaviour of 
the tumors that are ER positive, but not ESR1 amplified, in order to find a specific drug target for this 
subgroup. 
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A Norway/Stanford data set (n = 72) B Van’t Veer data set (n = 97)
 
Figure 12. Kaplan-Meier survival analysis of the Perou/Sorlie subgroups applied on two different 
breast cancer data sets: A) Norway/Stanford data set. B) Van't Veer data set. Modified from Sorlie et 
al (Sorlie et al., 2003). 
 
The other amplification we have focused our work on, was the 9p24 gene amplification. Similar to 
the ESR1 gene amplification, the amplicon revealed in one case a very small size of 0.7 Mb, only 
comprising the NFIB gene. This amplification has never been described in breast cancer, so far. One 
publication described once a 9p23-24 amplification in squamous cell carcinoma of the esophagus, but 
the authors reported that the most prominent amplified region harbors the GASC1 gene, which is 7 Mb 
away from the NFIB gene (Yang et al., 2001).  
Our findings from the FISH analysis on the Breast Prognosis TMA in combination with the RNA 
expression analysis strongly suggest the NFIB gene as the functionally important gene of the 9p24 
amplicon in breast cancer. Further, since NFIB gene amplified samples showed a higher proliferation 
index (Ki67 LI) and the NFIB RNA interference experiments resulted in reduced levels of 
proliferation, we advocate a proliferation supporting role for the NFIB protein. These findings are 
consistent with the already described properties of the members of the NFI family. The members of 
this family were first described as being required for the replication of Adenovirus DNA, later shown 
to regulate the transcription of a large variety of cellular and viral genes (reviewed in (Gronostajski, 
2000)). NFIB does also contain the DNA binding domain specific for the same palindromic sequence 
as the other members of the NFI family. Nevertheless, less is known about the NFIB protein. So far, 
the NFIB protein isoform with a MW of 47 kDa (SwissProt: NFIB_HUMAN) was handled as the so-
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called "normal" isoform. Our analyses revealed that the most prominent NFIB isoform in the cell lines 
tested was an isoform with a MW around 63 kDa. Further analyses of this isoform, especially 
regarding its potential target genes are still necessary. The analysis of an Affymetrix expression 
microarray public set (GSE 1456) comprising 159 breast cancers revealed an intriguing finding: 
samples belonging to the basal-like group of breast cancers showed a statistically significantly higher 
NFIB expression than samples belonging to the other molecular expression groups, previously 
described by Perou and Sorlie (Perou et al., 2000; Sorlie et al., 2001). An important role concerning 
NFIB in the basal-like breast cancers was strongly enforced by the results obtained from the 
evaluation of the DNA amplification levels on the Breast Prognosis TMA. NFIB gene amplification 
showed its highest rate on medullary carcinomas (19%, p = 0.0007). Interestingly, this subtype of 
breast carcinomas has recently been classified as breast cancers belonging to the basal-like expression 
group (Bertucci et al., 2006). In summary, we have shown that the NFIB gene is not only 
overexpressed in the basal group of breast cancers, but also amplified in a considerable fraction of 
them. These findings suggest that the NFIB gene is relevant for the development of these breast 
cancers. Our data from the NFIB gene knockdown experiments point towards a proliferation 
supporting role of NFIB in these cancers. 
 
Since we have found several new amplified regions in our limited study, we are convinced that the 
majority of the amplifications in breast cancer are still unknown. Our findings suggest the existence of 
a higher number of different amplifications than anticipated, but with a decreasing size. The two 
amplicons described in this work (the 9p24 and the 6q25) were smaller than 1 Mb. The most 
significant prerequisite for the detection of small gene amplifications is the resolution of the arrays 
used. We became aware of this when we investigated the most prominent gene amplification in breast 
cancer, the HER-2 gene amplification at 17q21. FISH analysis of the used breast cancer samples 
revealed four HER-2 amplified samples. Surprisingly, our bioinformatics approach was only able to 
confirm this result in two cases. Thorough informatic analysis of this region on the SNP array revealed 
an insufficient resolution of barely one SNP per Mb around the HER-2 gene locus. In addition, there 
was also a two Mb SNP-less region nearby this gene. Hence, only the detection of larger 
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amplifications on the 17q21 region was possible. Fortunately, most of the chromosomes were better 
resolved and could be used for the detection of small amplicons.  
In addition, we have to consider that our set comprised only 30 breast cancer samples and that most of 
the amplifications occur at a low rate. In order to enhance our chances, we selected only grade 3 breast 
cancers for the analysis, since these are known to harbor more amplifications. However, this is not 
necessarily the best selection since the ESR1 gene amplification was predominantly present in low 
grade tumors. 
 
For this study, we used the Affymetrix SNP 10k 2.0 arrays, since at the time this project started 
(spring 2004), these arrays were up-to-date. They consisted of 10'204 SNPs with a mean inter-SNP 
distance of 258 kb. In the mean time the actual high-end SNP arrays consist of 500'000 SNPs. In order 
to achieve a satisfactory resolution with the old type of microarrays, it was key to keep the noise level 
as low as possible. This was especially ambitious because we used breast cancer samples and these are 
known to be heterogeneous in cellular composition. Tissue pieces punched from the tumor will always 
be contaminated with a (small) fraction of non-tumorigenic cells. Since this noise is intrinsic, i.e. it has 
not been artificially added by a technical procedure, it is not possible to completely remove it. For this 
reason, the use of the reference set provided by Affymetrix comprising 110 normal human samples 
was not acceptable for our analysis. The bias generated by using a reference set, whose nature and 
processing was not performed in the same laboratory, was also criticized by other authors (Nannya et 
al., 2005). They even argued that the use of different PCR machines in the same laboratory may lead 
to significantly higher noise. Hence, we decided to develop our own analysis procedure which does 
not involve the use of an external reference set. We used a combination of freely available analysis 
tools, starting with the DChip software for normalization of the arrays. Between normalization and 
calculation of the DNA copy numbers, we implemented an additional smoothening step (Figure 9B). 
The appliance of the normalization, followed by this smoothening step, led to a tremendous increase in 
the signal-to-noise ratio (Figure 8). This was the major breakthrough which allowed us the detection of 
small-sized amplicons, like the NFIB (0.7 Mb) and the ESR1 (0.5 Mb) gene amplifications. These new 
amplifications are the smallest in size ever described in the literature. Many screenings for 
DISCUSSION 
 
 103
amplifications in breast cancer have been performed with high resolution array based CGH, but have 
never led to the new identification of such small single gene amplicons. 
 
The amplifications discovered in this study may represent only the tip of the iceberg, and not a 
complete profile. The findings of this study strongly indicate that there must be a huge number of 
undiscovered small-sized gene amplifications. Our novel methodology, combined with the 
improvements in array resolution and complexity, is expected to yield many more potential targets for 
cancer therapy in the future. 
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3.1. Conclusion 
In this work, we presented two new amplifications in breast cancer, the 9p24 amplicon comprising the 
NFIB gene, and the 6q25 amplicon with the ESR1 gene. The impact of the latter on breast cancer is 
indisputable, as we have demonstrated the relevance of its existence on decision making for therapy. 
In contrast, the NFIB gene is relatively unknown and additional work has to be performed in order to 
confirm its role in breast cancer, such as overexpression of the different NFIB isoforms. FISH analysis 
on a multi-tumor TMA would reveal if this gene amplification is present in other tumors than breast 
cancer. We already presented the first indication by showing its amplification in the non-breast tumor 
cell line S-117 (thyroid sarcoma). 
Importantly, this work shows that unconventional approaches, like the screening of 30 breast cancer 
samples, can be very successful. During the last 30 years, thousands of reports about the estrogen 
receptor and its role in breast cancer have been published, but until our discovery, the importance of 
its amplification was unknown. Hence, we suggest to repeat this study with at least 100 breast cancer 
samples comprising all kind of grades, but using a higher resolution, like the Affymetrix 1-Million-
SNP array which will be introduced in the near future. We are convinced that such a study would 
allow the detection of several very small gene amplifications and deletions with high impact on breast 
cancer development or even therapy. 
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5. Appendix 
5.1. Evaluation of reverse phase protein microarrays (lysate microarrays) 
5.1.1. Introduction 
Reverse phase protein microarrays (also called lysate microarrays) were first introduced in 2001 by 
Paweletz et al (Paweletz et al., 2001). Other authors have further developed this relatively new 
technique (Chan et al., 2004; Nishizuka et al., 2003). The principal aim was to establish a technique 
for the screening of molecular markers on the proteomic level. The principle of these microarrays 
involves a process of spotting cell extracts (protein lysates) from a large number of biological samples 
on a coated glass slide and subsequently probing the array with a large number of antibodies. The very 
low volume used for such an array spot (circa 0.3nL) allows the spotting of samples in several 
replicates in serial dilutions. This, in turn, does not only allow for the detection of the linear and 
dynamic range of binding of the used antibody, but also for the statistical evaluation of the retrieved 
data. Theoretically, up to 500 different tumor samples can be spotted on one glass slide. In order to 
circumvent the limitations of the tissue microarrays, such as the limited availability of antibodies 
suited for paraffin-embedded tissues, we wanted to establish the reverse phase protein microarray 
technology. We decided to use a dual-colour labelling and detection system in order to assess both, the 
protein of interest (e.g. HER-2) and the reference protein (e.g. GAPDH), simultaneously on the same 
array spot. 
 
5.1.2. Establishment of the best settings 
We selected a Cy3/Cy5 fluorescent labelling and detection system. In order to determine the best 
settings for the reverse phase protein microarray technology for our use, we spotted several tissue and 
cell line lysates onto different commercially available slides. Unfortunately, the protein binding 
capacity of almost all of the purchased slides was not sufficient for further use in a quantitative fashion 
(Figure S1 A left). Only the nitrocellulose coated slides from Schleicher&Schüll could be considered 
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further (Figure S1 A right), since the three-dimensional polymer coating of the nitrocellulose led to a 
higher surface area and thus to a higher binding capacity. Similar observations have been reported by 
other researchers ((Chan et al., 2004; Paweletz et al., 2001), Kallioniemi et al, personal 
communication). Optimizations of the environmental settings (e.g. humidity, spotting buffer used, pin 
diameter) enabled the production of nearly perfectly round spots, which are prerequisite for automated 
signal determination (Figure S1 B). The optimal spot morphology was confirmed by the achieved 
signal linearity of the dilution series (Figure S1 C). The linear region spanned at least five to six two-
fold dilutions (dilutions A1-A5, Figure S1 C), i.e. a 32-64 fold dilution range. This was accomplished 
either by using a GAPDH antibody in conjunction with a Cy5-coupled secondary antibody, or by 
using a total protein detection system that fluoresces near the Cy3 wavelength. Unfortunately, the 
usage of Cy3-coupled secondary antibodies was impracticable due to the nitrocellulose of the slides 
used which revealed an increasing background on more shorten wavelengths. The Cy3 system with a 
wavelength of around 560 nm (in contrast to Cy5 with 660nm), was strongly affected by this 
background. These findings made the use of a system in which both, the protein of interest and the 
reference protein were detected with Cy3-, respectively Cy5-coupled antibodies, impracticable. Hence, 
we decided to use the Cy3 channel only as reference for the determination of the total protein amount 
spotted. To this aim, the Deep Purple total protein detection (Amersham Biosciences) was selected. 
This procedure was feasible since the total protein amount was several times higher than the amount of 
a specific reference protein, and therefore above background and thus detectable. Obviously, the 
simultaneous detection of the protein of interest on the same slide was not possible any more. 
 
5.1.3. The Her-2 experiment 
In order to test our established reverse phase protein microarray system, we lysed 20 breast cancer 
tissue samples and four tumor cell lines. The samples were spotted in four two-fold dilutions on 
replicates (Figure S1 D). Deep Purple total protein detection system was used for the determination of 
total protein amount spotted. HER-2 was chosen as protein of interest and its expression was 
determined by usage of an anti-HER-2 antibody and a Cy5-coupled secondary antibody. Detection of 
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the spots and its signal quantification were done automatically by the scanner and its corresponding 
software. The two used channels (Cy3 and Cy5) were acquired separately, and the two images were 
overlaid, as shown in Figure S1 D. The Her-2 expression statuses of these samples were first 
determined independently from this study by using the commercially available Her-2 diagnostic kit 
(HercepTest, DAKO). Its scoring system ranges between 0 (no Her-2 expression) and 3+ (very high 
Her-2 protein expression). Two samples were classified as 3+ (sample 19 and the cell line SKBR3), 
one sample as 2+ (sample 11) and four samples (sample 15, 18 and the cell lines MCF7 and T47D) as 
1+. Using the total protein as reference, we determined the expression status of each of the spotted 
samples. The summary is shown as bar graph in Figure S1 E. The 3+ and 2+ positive samples could 
undoubtedly be detected in all of the cases. 
 
5.1.4. Discussion 
With this project, we showed the semi-successful establishment of the relatively new technology of 
the reverse phase protein microarrays. Several arising issues, like spot morphology, optimal 
environmental settings, determination of the linear range, could be solved. The experiment shown in 
Figure S1 D-E revealed that our system was capable to recognize and detect high expressing proteins, 
like Her-2 2+ and 3+ overexpressing samples, even when the data acquisition and evaluation was done 
in an automated manner. Nevertheless, we did not have the ability to detect the Her-2 1+ expressing 
samples, i.e. our system was not as sensitive as expected. We suggest that is due to the lack of a 
simultaneous incubation and detection system, in which both channels (Cy3 and Cy5) can be used. 
Since the FAST slides seem the most suited slides for the spotting of proteins, other investigators, 
which work with reverse phase protein microarrays, were confronted with similar problems. Chan et al 
(Chan et al., 2004) showed an interesting approach to handle this issue: they used a tyramide signal 
amplification system for the amplification of the Cy3 signal. This led to an usable signal above 
background, but also to a smaller linear range. Kallioniemi et al (personal communication) decided to 
replace the Cy3 detection with an infrared detection system. Since the wavelength of infrared signal is 
longer (> 700nm), the background diminishes and it can even be used as a double labelling and 
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detection system with the Cy5 channel (~650nm). Anyway, the acquisition of a scanner feasible for 
Cy5 and infrared signal is associated with tremendous costs. Finally, it can be summarized, that the 
idea of the reverse phase protein microarrays for screening of molecular markers on proteomic level, 
was very promising. But several issues, especially concerning the detection system have to be solved, 
first. The use of an infrared detection system is the first step in the right direction, but is accompanied 
be extremely high costs. 
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Figure S1. Reverse phase protein microarray experiments. A) shows the tremendous effect of the 
substratum on protein binding capacity. Left: epoxy-coated surface; right: nitrocellulose coated 
surface. B) Optimal parameter settings (humidity, buffer, substratum) leads to nearby perfect spot 
morphology. C) shows the linear range of a spotted dilution serie. The first five two-fold dilutions 
(A1-A5) can be used for data analysis. D) shows the Her-2 experiment. Image overlay of Deep Purple 
total protein detection (Cy3, green) and HER-2 antibody determination using a Cy5-coupled 
secondary antibody (red). E) shows the data analysis of the Her-2 experiment (D): Only the cell lines 
and samples that have an DAKO IHC score of 2+ or 3+ were detected as positive samples. 
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